nct_id stringlengths 11 11 | title stringlengths 23 300 | phase stringclasses 9
values | status stringclasses 13
values | study_type stringclasses 2
values | is_expanded_access bool 2
classes | sponsor stringlengths 5 100 | summary stringlengths 45 4.76k | interventions listlengths 1 12 | start_date stringlengths 0 10 | url stringlengths 44 44 | target_entities listlengths 0 5 | locations listlengths 0 104 | contact_phone stringlengths 0 29 | contact_email stringlengths 0 41 | eligibility dict | mechanism_summary dict |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NCT01082653 | Safety/Efficacy Study for the Treatment of Amyotrophic Lateral Sclerosis | PHASE1 | SUSPENDED | INTERVENTIONAL | false | TCA Cellular Therapy | A Phase I, single center, prospective, non-randomized, open label, safety/efficacy study of the infusion of autologous bone marrow-derived stem cells, in 6 patients with Amyotrophic Lateral Sclerosis according to established criteria (1), (2) with a moderate to severe diagnosis of ALS according to the World Federation ... | [
{
"type": "BIOLOGICAL",
"name": "autologous bone marrow-derived stem cells"
}
] | 2010-03 | https://clinicaltrials.gov/study/NCT01082653 | [] | [
{
"facility": "TCA Cellular Therapy",
"city": "Covington",
"state": "Louisiana",
"country": "United States",
"status": "",
"lat": 30.47549,
"lon": -90.10042
}
] | {
"criteria": "Inclusion Criteria:\n\n1. Adult male and female subjects \\> 18 years of age.\n2. Good understanding of the protocol and willingness to consent.\n3. Moderate to severe Diagnosis of ALS according to the World Federation of Neurology El Escorial criteria.\n4. Vital capacity at least 50% predicted value f... | {
"compound": "autologous bone marrow-derived stem cells",
"targeting_mechanism": "Stem cells differentiate into support cells such as astrocytes and oligodendrocytes, which benefit degenerating motor neurons by producing growth factors and anti-inflammatory cytokines, providing nutrients and buffering excessive gl... | ||
NCT02269436 | A follow-on Study to Assess Long-term Safety and Tolerability of i.c.v Administration of sNN0029 in Patients With ALS | PHASE1 | TERMINATED | INTERVENTIONAL | false | Newron Sweden AB | This is an open-label, follow-on phase 1 study to assess the long-term safety and tolerability of continuous i.c.v administration of 4 μg sNN0029/day in patients with ALS who previously participated in study sNN0029-003 | [
{
"type": "DRUG",
"name": "sNN0029 infusion solution"
}
] | 2015-01 | https://clinicaltrials.gov/study/NCT02269436 | [
"GDNF"
] | [
{
"facility": "Philip Van Damme",
"city": "Leuven",
"state": "",
"country": "Belgium",
"status": "",
"lat": 50.87959,
"lon": 4.70093
},
{
"facility": "Leonard van den Berg",
"city": "Utrecht",
"state": "",
"country": "Netherlands",
"status": "",
"lat": 52.0908... | {
"criteria": "Inclusion Criteria:\n\n1. Previous participation in sNN0029-003 with completion of 12 weeks study without clinically significant safety concerns\n2. Intact continuity of the Medtronic SynchroMed® II Infusion System as judged by X-ray of head and abdominal area\n3. Clinical diagnosis of ALS classified a... | {
"compound": "sNN0029",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "In SOD1G37R ALS mice, spinal subpial delivery of AAV9 shRNA-SOD1 silencing vector resulted in potent transduction of neuronal and glial cells throughout the spinal cord and blocked motoneuron degenerati... | ||
NCT02469675 | Brain and Nerve Stimulation for Hand Muscles in Spinal Cord Injury and ALS | NA | COMPLETED | INTERVENTIONAL | false | Bronx VA Medical Center | Most neurological injuries such as spinal cord injuries (SCI) and amyotrophic lateral sclerosis (ALS) spare a portion of nerve circuitry. Strengthening spared nerve circuits may be an important method to improve functional recovery.
In this study, the investigators aim to use non-invasive magnetic and electrical stimu... | [
{
"type": "DEVICE",
"name": "Transcranial magnetic stimulation"
},
{
"type": "DEVICE",
"name": "Median nerve stimulation"
},
{
"type": "DEVICE",
"name": "Cervical transcutaneous stimulation"
}
] | 2015-06 | https://clinicaltrials.gov/study/NCT02469675 | [
"motor_circuit_strengthening"
] | [
{
"facility": "James J. Peters VA Medical Center, Bronx, NY",
"city": "The Bronx",
"state": "New York",
"country": "United States",
"status": "",
"lat": 40.84985,
"lon": -73.86641
}
] | {
"criteria": "Inclusion Criteria:\n\n* Males or females age 21-65 years;\n* No history of serious neurological injury or disease; OR\n* Chronic (\\>12 months since injury) incomplete SCI between levels C2-C8 or diagnosis of definite or probable ALS;\n* Incomplete weakness of left or right hand muscles: score of 3 or... | {
"compound": "Transcranial magnetic stimulation, Median nerve stimulation, Cervical transcutaneous stimulation",
"targeting_mechanism": "Non-invasive magnetic and electrical stimulation to strengthen motor circuits between the brain and hands, targeting spared nerve circuitry to improve functional recovery.",
"t... | ||
NCT06607900 | hUC-MSC-sEV-001 Nasal Drops for Neurodegenerative Diseases | PHASE1 | NOT_YET_RECRUITING | INTERVENTIONAL | false | Xuanwu Hospital, Beijing | To evaluate the safety and preliminary efficacy of human umbilical cord mesenchymal stem cell-derived small extracellular vesicles hUC-MSC-sEV-001 nasal drops in multiple neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, multiple system atrophy, Lewy body dementia, frontotemporal dementia,... | [
{
"type": "DRUG",
"name": "hUC-MSC-sEV-001 nasal drops"
}
] | 2025-07-01 | https://clinicaltrials.gov/study/NCT06607900 | [
"neurodegeneration"
] | [
{
"facility": "Xuanwu Hospital, Capital Medical University",
"city": "Beijing",
"state": "Beijing Municipality",
"country": "China",
"status": "",
"lat": 39.9075,
"lon": 116.39723
}
] | 86-01-83198277 | haojunwei@vip.163.com | {
"criteria": "General Criteria:\n\nInclusion Criteria:\n\n1. Age 18-80 years (inclusive), any gender.\n2. Subjects or their legal guardians voluntarily sign a written informed consent form and are able to comply with the study requirements for dosing and follow-up.\n\nExclusion Criteria:\n\n1. Subjects who have rece... | {
"compound": "hUC-MSC-sEV-001",
"targeting_mechanism": "Human umbilical cord mesenchymal stem cell-derived small extracellular vesicles that may reduce neuroinflammation and oxidative stress in neurodegenerative diseases.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "... |
NCT07127172 | GB-PRIME: An Early Feasibility Study of a Precise Robotically Implanted Brain-Computer Interface for the Control of External Devices | NA | RECRUITING | INTERVENTIONAL | false | Neuralink Corp | The GB-PRIME Study is an early feasibility study designed to assess the clinical safety and functionality of the Neuralink N1 Implant and R1 Robot. This study involves participants who have tetraparesis, tetraplegia, or a diagnosis that may lead to these conditions.
The N1 Implant is a wireless, rechargeable device mo... | [
{
"type": "DEVICE",
"name": "N1 Implant"
},
{
"type": "DEVICE",
"name": "R1 Robot"
}
] | 2025-07-31 | https://clinicaltrials.gov/study/NCT07127172 | [] | [
{
"facility": "University College London Hospitals NHS Foundation Trust",
"city": "London",
"state": "Greater London",
"country": "United Kingdom",
"status": "RECRUITING",
"lat": 51.50853,
"lon": -0.12574
},
{
"facility": "The Newcastle upon Tyne Hospitals NHS Foundation Trust",
... | (877) 398-4465 | clinical-team-ct@neuralink.com | {
"criteria": "Inclusion Criteria:\n\n* (a) A diagnosis of a spinal cord injury, brain stem stroke, or other neurological condition causing the participant to be non-ambulant and with bilateral upper limb motor impairment with no expectation of recovery that significantly or completely impairs the participant's abili... | {
"compound": "N1 Implant, R1 Robot",
"targeting_mechanism": "A wireless, rechargeable brain-computer interface device with electrode threads implanted in the brain to enable control of external devices.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_fr... |
NCT05829330 | Ambulatory Versus Inpatient Initiation of Home Mechanical Ventilation | NA | COMPLETED | INTERVENTIONAL | false | Anne Kathrine Staehr-Rye | The purpose of this investigation is to see if outpatient initiation of noninvasive home mechanical ventilation combined with closed telemonitoring and follow-up in patients with amyotrophic lateral sclerosis is non-inferior to initiation during admission to the hospital
The primary hypothesis is that outpatient intia... | [
{
"type": "OTHER",
"name": "Outpatient"
},
{
"type": "OTHER",
"name": "Hospitalization"
}
] | 2023-09-20 | https://clinicaltrials.gov/study/NCT05829330 | [] | [
{
"facility": "Department of Anaesthesia, Pain and REspiratory Support",
"city": "Glostrup Municipality",
"state": "",
"country": "Denmark",
"status": "",
"lat": 55.6666,
"lon": 12.40377
}
] | {
"criteria": "Inclusion Criteria:\n\n* Age \\> 18 years\n* Diagnosed with amyotrophic lateral sclerosis\n* Indication for start of non-invasive mechanical ventilation\n\nExclusion Criteria:\n\n* No informed consent\n* Does not understand Danish or English\n* Indication for invasive mechanical ventilation\n* No morni... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT04998305 | TJ-68 Clinical Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) and Muscle Cramps | PHASE1, PHASE2 | COMPLETED | INTERVENTIONAL | false | Hiroshi Mitsumoto | The primary objective of the study is to demonstrate the safety and potential efficacy of TJ-68 for improving muscle cramps in participants with ALS based on a two-site, randomized, placebo-controlled double-blind multi-period crossover (N-of-1) study design. | [
{
"type": "DRUG",
"name": "TJ-68"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2022-09-30 | https://clinicaltrials.gov/study/NCT04998305 | [
"muscle_cramps"
] | [
{
"facility": "Mayo Clinic",
"city": "Scottsdale",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.50921,
"lon": -111.89903
},
{
"facility": "Mayo Clinic",
"city": "Jacksonville",
"state": "Florida",
"country": "United States",
"status": ""... | {
"criteria": "Inclusion Criteria:\n\n* Diagnosed with ALS, PMA or PLS based on the El Escorial ALS Diagnostic Criteria or based on more recently revised Gold Coast ALS diagnostic criteria\n* Experiences at least one muscle cramp in any muscle per day\n* Age 20 to 84 years old\n* Forced vital capacity is 45% of norma... | {
"compound": "TJ-68",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT06973629 | Efficacy and Safety of MSC-NTF (NurOwn) in Participants With Early Symptomatic ALS and Moderate Disease Presentation in ALS (ENDURANCE STUDY) | PHASE3 | NOT_YET_RECRUITING | INTERVENTIONAL | false | Brainstorm-Cell Therapeutics | The goal of this two-part clinical trial is:
1\) to evaluate the safety and efficacy of Debamestrocel - MSC-NTF (NurOwn) compared to placebo in participants with early symptomatic ALS and moderate disease presentation in ALS; followed by 2) further evaluation by providing NurOwn to all participants in an open label ex... | [
{
"type": "BIOLOGICAL",
"name": "Debamestrocel - MSC-NTF (NurOwn)"
},
{
"type": "BIOLOGICAL",
"name": "Placebo"
}
] | 2025-06-30 | https://clinicaltrials.gov/study/NCT06973629 | [
"neurotrophic_factors"
] | [
{
"facility": "Barrow Neurological Institute",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "University of California San Diego Medical Center",
"city": "La Jolla",
"state": "Californi... | 201-488-0460 | ClinicalTrial@Brainstorm-cell.com | {
"criteria": "Inclusion Criteria:\n\n1. Male and female participants 18 to 75 years old (inclusive) at Screening Visit 1.\n2. ALS diagnosed as laboratory-supported probable, clinically probable, or definite as defined by the revised El Escorial criteria.\n3. Having onset of ALS symptoms, including muscle weakness, w... | {
"compound": "Debamestrocel - MSC-NTF (NurOwn)",
"targeting_mechanism": "Mesenchymal stromal cells engineered to secrete neurotrophic factors that provide trophic support to degenerating motor neurons.",
"targeting_mechanism_pmid": "32043626",
"animal_results": "Bone marrow-derived mesenchymal stem cells showe... |
NCT07209943 | Augmented Reality BCI Longitudinal Study for Persons With ALS, Stroke, TBI and SCI Utilizing Cognixion + Apple Vision Pro | NA | NOT_YET_RECRUITING | INTERVENTIONAL | false | Cognixion | The goal of this study is refine the usability of a BCI capable communication platform.
The study will take place in the United States area and will enroll up to 10 participants with late stage ALS, traumatic brain injury (TBI) or spinal cord injury (SCI) that have assistive communication and computer control needs. E... | [
{
"type": "DEVICE",
"name": "Cognixion + Apple Vision Pro"
}
] | 2025-10-16 | https://clinicaltrials.gov/study/NCT07209943 | [] | [
{
"facility": "Cognixion HQ",
"city": "Santa Barbara",
"state": "California",
"country": "United States",
"status": "",
"lat": 34.42083,
"lon": -119.69819
}
] | 18053200774 | chris@cognixion.com | {
"criteria": "Inclusion criteria:\n\n* Must have a designated on-site support individual who can be trained on the Cognixion system\n* Fluent in understanding English\n* 18 years or older\n* Must have one of ALS, spinal cord injury or chronic brain injury and need an assistive communication device\n* Must be able to... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
NCT02000713 | Cervical Spinal Cord Metabolism and Microstructure in Amyotrophic Lateral Sclerosis(ALS) | NA | TERMINATED | INTERVENTIONAL | false | University of Michigan | The investigators want to know if magnetic resonance imaging can accurately provide an early diagnosis of amyotrophic lateral sclerosis (ALS). | [
{
"type": "OTHER",
"name": "MRI"
},
{
"type": "OTHER",
"name": "Clinical Exam"
}
] | 2013-10 | https://clinicaltrials.gov/study/NCT02000713 | [] | [
{
"facility": "University of Michigan Hospital",
"city": "Ann Arbor",
"state": "Michigan",
"country": "United States",
"status": "",
"lat": 42.27756,
"lon": -83.74088
}
] | {
"criteria": "Inclusion Criteria:\n\n1\\. Adults age 18 to 80 years of age.\n\nExclusion Criteria:\n\n1. Do not have active substance abuse\n2. Do not have co-morbid psychiatric disease\n3. Do not have opportunistic central nervous system infection\n4. Do not have cerebrovascular disease\n5. Do not have a contraindi... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT01758510 | Safety Study of HLA-haplo Matched Allogenic Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis | PHASE1 | COMPLETED | INTERVENTIONAL | false | Hanyang University Seoul Hospital | The purpose of this study is to evaluate the safety of HLA-haplo matched Allogenic Bone Marrow Derived stem cells("HYNR-CS-Allo inj"), through intrathecal delivery for the treatment in patients with amyotrophic lateral sclerosis(ALS).
This study is an open label, dose up and down study using the 3+3 design to assess t... | [
{
"type": "GENETIC",
"name": "HYNR-CS-Allo"
}
] | 2012-12 | https://clinicaltrials.gov/study/NCT01758510 | [
"neurodegeneration"
] | [
{
"facility": "Hanyang University Seoul Hospital, Cell Therapy Center for Neurologic Disorders",
"city": "Seoul",
"state": "Haengdang-dong, Seongdong-gu",
"country": "South Korea",
"status": "",
"lat": 37.566,
"lon": 126.9784
}
] | {
"criteria": "Inclusion Criteria:\n\n* Patients between 25 and 80 years old\n* Patients who have both signs of lower motor neuron(LMN) and upper motor neuron(UMN) degeneration by clinical, electrophysiological or neuropathologic examination\n* Patients diagnosed as 'Probable' or 'Definite' ALS according to the World... | {
"compound": "HYNR-CS-Allo",
"targeting_mechanism": "HLA-haplo matched allogeneic bone marrow-derived stem cells delivered intrathecally to promote neuroprotection and reduce neuroinflammation in ALS.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from... | ||
NCT06454682 | An IIT Clinical Study to Evaluate the Safety and Efficacy of a Single Intrathecal Injection of RJK002 in Patients With ALS | EARLY_PHASE1 | ACTIVE_NOT_RECRUITING | INTERVENTIONAL | false | RJK Biopharma Ltd | The goal of this clinical trial is to evaluate the safety and efficacy of a single intrathecal injection of RJK002 in patients with Amyotrophic Lateral Sclerosis (ALS). The main questions it aims to answer are:
* The safety, tolerability, and preliminary efficacy of a single intrathecal injection of RJK002 in subjects... | [
{
"type": "DRUG",
"name": "RJK002 Intrathecal injection"
}
] | 2023-09-11 | https://clinicaltrials.gov/study/NCT06454682 | [
"gene_therapy_aav_vector"
] | [
{
"facility": "The First Affiliated Hospital Fujian Medical University",
"city": "Fuzhou",
"state": "Fujian",
"country": "China",
"status": "",
"lat": 26.06139,
"lon": 119.30611
}
] | {
"criteria": "Inclusion Criteria:\n\n1. Female or male subjects who are ≥ 18 years of age at screening;\n2. Patients with a diagnosis consistent with clinically or laboratory-supported possible, probable, or definite sporadic or familial ALSALS in accordance with Revised EI Escorial diagnostic criteria published by ... | {
"compound": "RJK002",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT06051123 | Effects of Probiotics in Amyotrophic Lateral Sclerosis-Frontotemporal Dementia Spectrum Disorder (ALS-FTDSD) Patients | NA | RECRUITING | INTERVENTIONAL | false | Centre hospitalier de l'Université de Montréal (CHUM) | The aim of this study is to assess the impact of a probiotic formulation on participants with ALS-FTDSD. It is hypothesized that participants given the probiotics will have different lipid profiles compared to participants receiving the placebo at different time points. | [
{
"type": "DIETARY_SUPPLEMENT",
"name": "Probiotic"
},
{
"type": "DIETARY_SUPPLEMENT",
"name": "Placebo"
}
] | 2024-01-01 | https://clinicaltrials.gov/study/NCT06051123 | [
"microbiome"
] | [
{
"facility": "Stan Cassidy Centre for Rehabilitation",
"city": "Fredericton",
"state": "New Brunswick",
"country": "Canada",
"status": "RECRUITING",
"lat": 45.94541,
"lon": -66.66558
},
{
"facility": "Centre Hospitalier de l'Université de Montréal",
"city": "Montreal",
"... | 514-890-8000 | amelie.bujold.chum@ssss.gouv.qc.ca | {
"criteria": "Inclusion criteria:\n\nParticipants must meet all of the following inclusion criteria to be eligible for enrolment into the study:ALS-FTDSD participants\n\n1. Aged 18 years old or greater.\n2. Diagnosis of ALS by El Escorial Criteria revised (possible, probable, probable with lab support and definite).... | {
"compound": "Probiotic formulation",
"targeting_mechanism": "Modulation of gut microbiota composition to reduce dysbiosis and associated neuroinflammation in ALS.",
"targeting_mechanism_pmid": "28129947",
"animal_results": "Dysbiosis in ALS is linked to alterations in microbial composition and metabolic dysfu... |
NCT03929068 | Sinemet for Spasticity and Function in Amyotrophic Lateral Sclerosis and Primary Lateral Sclerosis | PHASE1 | COMPLETED | INTERVENTIONAL | false | Washington University School of Medicine | Motivated by the success of dopaminergic drugs in treating rigidity associated with Parkinson's disease, some neurologists have used carbidopa-levodopa (Sinemet) to attempt to improve spasticity in ALS and PLS patients. However, data on the efficacy of carbidopa/levodopa is limited. Given the limited data and potential... | [
{
"type": "DRUG",
"name": "carbidopa-levodopa"
},
{
"type": "DRUG",
"name": "Placebo Oral Tablet"
}
] | 2019-05-13 | https://clinicaltrials.gov/study/NCT03929068 | [
"dopamine_pathway"
] | [
{
"facility": "Washington University School of Medicine",
"city": "St Louis",
"state": "Missouri",
"country": "United States",
"status": "",
"lat": 38.62727,
"lon": -90.19789
}
] | {
"criteria": "Inclusion Criteria:\n\n* Diagnosis of ALS or PLS\n* Age greater than 18 years\n* Clinically significant spasticity.\n\nExclusion Criteria:\n\n* Individuals currently taking carbidopa-levodopa or with known hypersensitivity of any component of carbidopa-levodopa\n* Narrow-angle glaucoma\n* Current use o... | {
"compound": "carbidopa-levodopa",
"targeting_mechanism": "Dopaminergic agonist that enhances dopamine neurotransmission to reduce spasticity by targeting dopamine deficiency pathways.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "Parkinson's ... | ||
NCT06689982 | Tofacitinib in Patients With Amyotrophic Lateral Sclerosis | EARLY_PHASE1 | NOT_YET_RECRUITING | INTERVENTIONAL | false | Beijing Tiantan Hospital | Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease, of which motor-neuron's degeneration may be associated with neuroinflammation. Tofacitinib is a Janus kinase (JAK) inhibitor that affects cellular hematopoiesis and cellular immune function. At the same time, tofacitinib is suitable for rheumatoi... | [
{
"type": "DRUG",
"name": "Tofacitinib tablets"
}
] | 2024-12-01 | https://clinicaltrials.gov/study/NCT06689982 | [
"JAK",
"neuroinflammation"
] | [
{
"facility": "Beijing Tiantan Hospital",
"city": "Beijing",
"state": "",
"country": "China",
"status": "",
"lat": 39.9075,
"lon": 116.39723
}
] | 0086-010-67092222 | yilong528@aliyun.com | {
"criteria": "Inclusion Criteria:\n\n* 18 years old≤ age≤ 75 years old, males or females;\n* Forced vital capacity ≥ 60% of predicted vital capacity during the screening period;\n* The diagnosis conforms to the diagnostic criteria for amyotrophic lateral sclerosis on the Gold Coast;\n* Based on the analysis of wheth... | {
"compound": "Tofacitinib",
"targeting_mechanism": "JAK (Janus kinase) inhibitor that suppresses neuroinflammation by reducing cellular hematopoiesis and immune function, targeting the role of neuroinflammation in motor neuron degeneration.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"anim... |
NCT01849770 | Mexiletine in Sporadic Amyotrophic Lateral Sclerosis (SALS) | PHASE2 | COMPLETED | INTERVENTIONAL | false | University of Washington | The purpose of this research is to find out if mexiletine is safe and effective in people with Amyotrophic Lateral Sclerosis (ALS). In this trial, participants will be taking either 300 milligrams per day of mexiletine, 900 milligrams per day of mexiletine or placebo (non-active study drug). The safety and efficacy of ... | [
{
"type": "DRUG",
"name": "Mexiletine"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2013-07 | https://clinicaltrials.gov/study/NCT01849770 | [
"Sodium channel"
] | [
{
"facility": "UCLA, Neuromuscular Research Center",
"city": "Los Angeles",
"state": "California",
"country": "United States",
"status": "",
"lat": 34.05223,
"lon": -118.24368
},
{
"facility": "University of Iowa",
"city": "Iowa City",
"state": "Iowa",
"country": "Uni... | {
"criteria": "Inclusion Criteria:\n\n* Sporadic Amyotrophic Lateral Sclerosis (SALS) diagnosed as possible, laboratory-supported probable, probable, or definite ALS as defined by revised El Escorial criteria.\n* Age 18 years or older.\n* Disease duration ≤ 36 months from ALS symptom onset.\n* Capable of providing in... | {
"compound": "Mexiletine",
"targeting_mechanism": "Mexiletine is a local anesthetic with sodium channel blocking properties that may protect motor neurons.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT00324454 | Levetiracetam for Cramps, Spasticity and Neuroprotection in Motor Neuron Disease | PHASE2 | COMPLETED | INTERVENTIONAL | false | Duke University | Levetiracetam (Keppra) is used to treat partial onset seizures. Its biological effects suggest it might also be useful in treating 3 aspects of human motor neuron diseases (MNDs) for which no effective therapy exists: cramps, spasticity, and disease progression. | [
{
"type": "BIOLOGICAL",
"name": "Levetiracetam"
}
] | 2006-05 | https://clinicaltrials.gov/study/NCT00324454 | [
"gaba_pathway"
] | [
{
"facility": "Duke University ALS Clinic - 932 Morreene Road",
"city": "Durham",
"state": "North Carolina",
"country": "United States",
"status": "",
"lat": 35.99403,
"lon": -78.89862
}
] | {
"criteria": "Inclusion Criteria:\n\n* Patients with MNDs (ALS, PLS or PMA)who have cramps with average severity 50/100 points, are able to provide informed consent, have normal renal function and are on a stable riluzole dose.\n\nExclusion Criteria:\n\n* Pregnancy; unstable medical illness, dementia; drug abuse or ... | {
"compound": "Levetiracetam",
"targeting_mechanism": "Levetiracetam is an anti-seizure medication whose biological effects suggest potential neuroprotective mechanisms for treating cramps, spasticity, and disease progression in motor neuron disease.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown"... | ||
NCT00596115 | Treating Amyotrophic Lateral Sclerosis (ALS) With R(+) Pramipexole Dihydrochloride Monohydrate at 60 mg/Day | Expanded Access | TEMPORARILY_NOT_AVAILABLE | EXPANDED_ACCESS | true | Bennett, James P., Jr., M.D., Ph.D. | R(+) pramipexole dihydrochloride monohydrate \[R(+)PPX\], an experimental neuroprotective drug, is provided in this open label extension study to ALS patients who have participated in earlier clinical protocols. | [
{
"type": "DRUG",
"name": "R(+) pramipexole dihydrochloride monohydrate"
}
] | https://clinicaltrials.gov/study/NCT00596115 | [
"Dopamine D3 receptor"
] | [] | {
"criteria": "Inclusion Criteria:\n\n* Definite diagnosis of ALS\n\nExclusion Criteria:\n\n* No prior participation in R(+)PPX clinical studies",
"sex": "ALL",
"min_age": "30 Years",
"max_age": "80 Years",
"healthy_volunteers": null,
"std_ages": [
"ADULT",
"OLDER_ADULT"
]
} | {
"compound": "R(+) pramipexole dihydrochloride monohydrate",
"targeting_mechanism": "R(+) pramipexole is a dopamine receptor agonist with experimental neuroprotective properties in ALS.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
... | |||
NCT01551940 | Toxin Treatment for Amyotrophic Lateral Sclerosis (ALS) Related Sialorrhea | PHASE2 | COMPLETED | INTERVENTIONAL | false | Hospices Civils de Lyon | Evaluation of the decrease of the secretion of saliva in patients with amyotrophic lateral sclerosis by a local ultrasound-guided bilateral injection of botulinum toxin type A in parotids and submandibular glands. The investigators want to demonstrate 1 month after the injection, by a multicenter French randomized doub... | [
{
"type": "DRUG",
"name": "Botox injection"
},
{
"type": "DRUG",
"name": "Placebo injection"
}
] | 2012-02 | https://clinicaltrials.gov/study/NCT01551940 | [
"acetylcholine_signaling"
] | [
{
"facility": "Département de Neurologie, Hôpital de l'Hôtel-Dieu, CHU d'Angers",
"city": "Angers",
"state": "",
"country": "France",
"status": "",
"lat": 47.47156,
"lon": -0.55202
},
{
"facility": "Centre SLA, Groupement Hospitalier Est, Hôpital Neurologique Pierre Wertheimer, H... | {
"criteria": "Inclusion Criteria:\n\n* Age \\> 18 years\n* Obtaining of a written consent after information\n* Diagnosis of probable or certain ALS according to the El Escorial criteria of the World Federation and Neurology Committee on Neuromuscular Diseases\n* Patient having a follow-up in an ALS center\n* Sialorr... | {
"compound": "Botulinum toxin type A",
"targeting_mechanism": "Botulinum toxin type A blocks acetylcholine release at the neuromuscular junction to reduce excessive salivation in ALS-related sialorrhea.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_fr... | ||
NCT02936635 | A Study for Patients Who Completed VITALITY-ALS (CY 4031) | PHASE3 | COMPLETED | INTERVENTIONAL | false | Cytokinetics | The purpose of this study is to assess the long-term safety and tolerability of tirasemtiv in patients with ALS who had completed the double-blind placebo-controlled study of tirasemtiv in ALS (CY 4031). | [
{
"type": "DRUG",
"name": "tirasemtiv"
}
] | 2016-10-17 | https://clinicaltrials.gov/study/NCT02936635 | [
"Troponin complex"
] | [
{
"facility": "St. Joseph's Hospital and Medical Center - Barrow Neurology Clinics",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "Cedars-Sinai Medical Center",
"city": "Los Angeles",
... | {
"criteria": "Inclusion Criteria:\n\n* Able to comprehend and willing to sign an Informed Consent Form (ICF). If verbal consent is given, a Legal Designee of the patient must sign the ICF form\n* Completed participation on study drug and the Follow-Up Visit in the CY 4031 study\n* Male patients, who have not had a v... | {
"compound": "Tirasemtiv",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT03049046 | CC100: Phase 1 Multiple-Dose Safety and Tolerability in Subjects With ALS | PHASE1 | UNKNOWN | INTERVENTIONAL | false | Chemigen, LLC | Approximately 21 subjects with amyotrophic lateral sclerosis (ALS) will be randomized (6 to 1) to receive by mouth seven morning doses of CC100 or placebo for 7 days. Subjects are required to stay in the Clinic for approximately 9 hours following the first and last dose. Subjects will also have a mid-week clinic visit ... | [
{
"type": "DRUG",
"name": "CC100"
},
{
"type": "DRUG",
"name": "Placebos"
}
] | 2017-04-07 | https://clinicaltrials.gov/study/NCT03049046 | [
"cc100"
] | [
{
"facility": "Indiana University, IU Health Physicians Neurology",
"city": "Indianapolis",
"state": "Indiana",
"country": "United States",
"status": "RECRUITING",
"lat": 39.76838,
"lon": -86.15804
}
] | {
"criteria": "Inclusion Criteria:\n\n* Have definite or probable ALS with a forced vital capacity of \\>60% predicted.\n* Men must practice a reliable method of birth control during study and for 2 weeks following study. Women must be non-fertile or post-menopausal.\n* Riluzole is allowed if dose has been stable for... | {
"compound": "CC100",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT01879241 | Study of Rasagiline in Patients With Amyotrophic Lateral Sclerosis | PHASE2 | COMPLETED | INTERVENTIONAL | false | University of Ulm | The primary objective of the trial is to investigate the survival time (the time from randomization until death or end of the trial) compared between control group and experimental group.
This is a prospective, multicenter, randomized, stratified, parallel-group, double-blind trial comparing placebo with 1 mg/d rasagi... | [
{
"type": "DRUG",
"name": "Rasagiline"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2013-06 | https://clinicaltrials.gov/study/NCT01879241 | [
"MAOA"
] | [
{
"facility": "Department of Neurology, University of Ulm",
"city": "Ulm",
"state": "Baden-Wurttemberg",
"country": "Germany",
"status": "",
"lat": 48.39841,
"lon": 9.99155
},
{
"facility": "Department of Neurology, Technische Universität München",
"city": "Munich",
"stat... | {
"criteria": "Inclusion Criteria:\n\n* Possible, probable (clinically or laboratory) or definite ALS according to the revised version of the El Escorial World Federation of Neurology criteria\n* Disease duration more than 6 months and less than 3 years (inclusive). Disease onset defined as date of first muscle weakn... | {
"compound": "Rasagiline",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT01999803 | A Safety Study of sNN0029 Administration Via Intracerebroventricular Route to Patients With ALS | PHASE1 | TERMINATED | INTERVENTIONAL | false | Newron Sweden AB | This is a phase I, multicentre randomised, double-blind, placebo-controlled trial to assess the safety and tolerability of continuous i.c.v. administration of sNN0029 infusion solution at a dose of 4µg/day in patients with Amyotrophic Lateral Sclerosis (ALS). | [
{
"type": "DRUG",
"name": "sNN0029"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2014-09 | https://clinicaltrials.gov/study/NCT01999803 | [
"snn0029"
] | [
{
"facility": "Philip Van Damme",
"city": "Leuven",
"state": "",
"country": "Belgium",
"status": "",
"lat": 50.87959,
"lon": 4.70093
},
{
"facility": "Leonard van den Berg",
"city": "Utrecht",
"state": "",
"country": "Netherlands",
"status": "",
"lat": 52.0908... | {
"criteria": "Inclusion Criteria:\n\n* Clinical diagnosis of ALS classified as definite, or probable with or without additional laboratory evidence, according to the revised World Federation of Neurology (WFN) El Escorial criteria.\n* If patients are being treated with riluzole, they must have been on a stable dose ... | {
"compound": "sNN0029",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT02759003 | Nightime NIV Initiation in Amyotrophic Lateral Sclerosis in an Outpatient Setting | NA | COMPLETED | INTERVENTIONAL | false | Fondazione Salvatore Maugeri | In patients with amyotrophic lateral sclerosis (ALS), non-invasive mechanical ventilation (NIV) is usually initiated in an in-hospital regime. The investigators evaluated if NIV initiated in an outpatient setting can be as effective as regards patients' adherence. The investigators also evaluated factors predicting NIV... | [
{
"type": "PROCEDURE",
"name": "Nightime NIV initiation"
}
] | 2011-03 | https://clinicaltrials.gov/study/NCT02759003 | [] | [] | {
"criteria": "Inclusion Criteria:\n\n* consecutive patients\n* definite ALS diagnosis\n* aged \\> 18 years\n* in clinically stable condition\n* referred to the ALS outpatient clinics of the Fondazione Salvatore Maugeri Institute of Lumezzane (Brescia) and the Istituto Don Gnocchi Onlus (Milano), Italy for respirator... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT07093268 | Safety of Intrathecal Riluzole in Patients With Amyotrophic Lateral Sclerosis | PHASE1 | NOT_YET_RECRUITING | INTERVENTIONAL | false | Brain Trust Bio | The purpose of this study is to investigate the safety and tolerability of intrathecal riluzole in adults with amyotrophic lateral sclerosis. | [
{
"type": "DRUG",
"name": "Intrathecal Riluzole"
}
] | 2025-08-15 | https://clinicaltrials.gov/study/NCT07093268 | [
"riluzole"
] | [
{
"facility": "Sunshine Coast University Hospital",
"city": "Birtinya",
"state": "Queensland",
"country": "Australia",
"status": "",
"lat": -26.74322,
"lon": 153.11913
},
{
"facility": "Flinders Medical Centre",
"city": "Bedford Park",
"state": "South Australia",
"cou... | +1 857 285 8300 | chen.benkler@gmail.com | {
"criteria": "Inclusion Criteria:\n\n* Men and women aged 18 years or older.\n* Participants are ambulatory with or without an assistive device.\n* Sporadic or familial ALS diagnosis with possible, laboratory-supported probable, probable, or definite as defined by revised El Escorial criteria.\n* Slow vital capacity... | {
"compound": "Riluzole",
"targeting_mechanism": "Riluzole blocks glutamatergic neurotransmission in the CNS to exert neuroprotective effects.",
"targeting_mechanism_pmid": "32847483",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
NCT00230074 | A Long-term Extension Study of TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis(ALS) | PHASE2 | COMPLETED | INTERVENTIONAL | false | Novartis | This is a study to evaluate the safety and clinical effects of 4 oral doses of TCH346 compared to placebo in patients with mild or mild to moderate stages of ALS. | [
{
"type": "DRUG",
"name": "TCH346"
}
] | 2004-11 | https://clinicaltrials.gov/study/NCT00230074 | [
"tch346"
] | [
{
"facility": "Novartis",
"city": "East Hanover",
"state": "New Jersey",
"country": "United States",
"status": "",
"lat": 40.8201,
"lon": -74.36487
}
] | {
"criteria": "Inclusion Criteria:\n\n* Completed original protocol, Study No. CTCH346A2211\n* Be capable of satisfying the requirements of the extension protocol and must sign informed consent after the nature of the extension protocol has been fully explained\n\nExclusion Criteria:\n\n* Exclusion criteria as descri... | {
"compound": "TCH346",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT02868580 | Safety and Tolerability of Antiretroviral (Triumeq) in Patients With Amyotrophic Lateral Sclerosis (ALS). | PHASE2 | COMPLETED | INTERVENTIONAL | false | Neuroscience Trials Australia | This is a phase 2a open label, multicentre design study to investigate the safety of Triumeq in patients with ALS at 24 weeks post treatment. In this phase 2a study the investigators aim to determine whether a combination of anti-retroviral therapy, Triumeq (dolutegravir 50mg, abacavir 600mg, lamivudine 300mg) is toler... | [
{
"type": "DRUG",
"name": "Triumeq"
}
] | 2016-10 | https://clinicaltrials.gov/study/NCT02868580 | [
"triumeq"
] | [
{
"facility": "Macquarie Neurology",
"city": "North Ryde",
"state": "New South Wales",
"country": "Australia",
"status": "",
"lat": -33.79677,
"lon": 151.12436
},
{
"facility": "Westmead Hospital",
"city": "Parramatta",
"state": "New South Wales",
"country": "Australi... | {
"criteria": "Inclusion Criteria:\n\nSubjects must meet all of the following inclusion criteria to be eligible to participate in this study:\n\n* Age 18-75 years at the time of the screening visit\n* Able to provide informed consent and comply with study procedures\n* Sporadic ALS diagnosed as probable, laboratory-s... | {
"compound": "Triumeq",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT05740813 | HEALEY ALS Platform Trial - Regimen F ABBV-CLS-7262 | PHASE2, PHASE3 | COMPLETED | INTERVENTIONAL | false | Merit E. Cudkowicz, MD | The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.
Regimen F will evaluate the safety and efficacy of a single study drug, ABBV-CLS-7262, in participants with ALS. | [
{
"type": "DRUG",
"name": "ABBV-CLS-7262 Dose 1"
},
{
"type": "DRUG",
"name": "ABBV-CLS-7262 Dose 2"
},
{
"type": "DRUG",
"name": "Matching Placebo"
}
] | 2023-03-23 | https://clinicaltrials.gov/study/NCT05740813 | [
"abbv_cls_7262"
] | [
{
"facility": "Healey Center for ALS at Mass General",
"city": "Boston",
"state": "Massachusetts",
"country": "United States",
"status": "",
"lat": 42.35843,
"lon": -71.05977
}
] | {
"criteria": "Inclusion Criteria:\n\n* No additional inclusion criteria beyond the inclusion criteria specified in the Master Protocol (NCT NCT04297683).\n\nExclusion Criteria:\n\n* The following exclusion criteria are in addition to the exclusion criteria specified in the Master Protocol (NCT NCT04297683).\n\n 1. ... | {
"compound": "ABBV-CLS-7262",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT05041114 | SWITCH II Early Feasibility Study: Implantable BCI to Control a Digital Device for People With Paralysis | NA | WITHDRAWN | INTERVENTIONAL | false | Synchron Medical, Inc. | The Synchron Motor Neuroprosthesis (MNP) is intended to be used in subjects with severe motor impairment, unresponsive to medical or rehabilitative therapy and a persistent functioning motor cortex. The purpose of this research is to evaluate safety and feasibility.
The MNP is a type of implantable brain computer inte... | [
{
"type": "DEVICE",
"name": "Motor Neuroprosthesis"
}
] | 2022-04-21 | https://clinicaltrials.gov/study/NCT05041114 | [] | [
{
"facility": "Sydney Local Health District",
"city": "Sydney",
"state": "New South Wales",
"country": "Australia",
"status": "",
"lat": -33.86785,
"lon": 151.20732
},
{
"facility": "Metro North Health",
"city": "Brisbane",
"state": "Queensland",
"country": "Australia... | {
"criteria": "Inclusion Criteria:\n\n1. Severe motor impairment\n2. Able to give consent\n3. Appropriate candidate for neurointerventional procedure\n4. Able and willing to access all clinical testing and not impeded by geographical location\n5. Proficient in English\n6. Have a study partner\n\nExclusion Criteria:\n... | {
"compound": "Motor Neuroprosthesis",
"targeting_mechanism": "An implantable brain-computer interface that bypasses dysfunctional motor neurons to restore transmission of neural signals from the cerebral cortex for neuromuscular control.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_... | ||
NCT00965497 | Escitalopram (Lexapro) for Depression MS or ALS | PHASE3 | COMPLETED | INTERVENTIONAL | false | University of South Carolina | The purpose of this study is to see if escitalopram (Lexapro) improves symptoms of major depressive disorder in patients who have ALS or MS. | [
{
"type": "DRUG",
"name": "escitalopram"
}
] | 2009-07 | https://clinicaltrials.gov/study/NCT00965497 | [
"SLC6A4"
] | [
{
"facility": "University of South Carolina School of Medicine",
"city": "Columbia",
"state": "South Carolina",
"country": "United States",
"status": "",
"lat": 34.00071,
"lon": -81.03481
}
] | {
"criteria": "Inclusion Criteria:\n\n* Patients between 18 and 70 years of age with documented ALS or MS,\n* DSM-IV episode of non-psychotic Major Depression,\n* ≥14 score on the 17-item HAM-D,\n* Ability to give informed consent.\n\nExclusion Criteria:\n\n* History of psychotic disorders,\n* Psychotic depression,\n... | {
"compound": "escitalopram",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT03835507 | Randomized, Double-blind, Safety and Efficacy of Recombinant Human Erythropoietin in Amyotrophic Lateral Sclerosis | PHASE1, PHASE2 | UNKNOWN | INTERVENTIONAL | false | Hanyang University Seoul Hospital | Erythropoietin is neuroprotective in animal models of neurodegenerative diseases including amyotrophic lateral sclerosis (ALS). The aim of this study was to determine the safety and feasibility of repetitive high-dose recombinant human erythropoietin (rhEPO) therapy in ALS patients. | [
{
"type": "DRUG",
"name": "recombinant human erythropoietin(rhEPO)"
}
] | 2016-06-20 | https://clinicaltrials.gov/study/NCT03835507 | [
"EPO"
] | [
{
"facility": "Hanyang Medical Center",
"city": "Seoul",
"state": "",
"country": "South Korea",
"status": "RECRUITING",
"lat": 37.566,
"lon": 126.9784
}
] | +82-2-2290-8367 | jinseok.park0@gmail.com | {
"criteria": "Inclusion Criteria:\n\n* Age between 25 to 80\n* upper motor neuron signs and lower motor neuron signs were identified in neurological examination.\n* Meet the revised El Escorial Criteria for clinically possible, probable-laboratory -supported, probable, definite ALS.\n* Disease duration \\< 3 years (... | {
"compound": "recombinant human erythropoietin (rhEPO)",
"targeting_mechanism": "Neuroprotective agent that reduces neurodegeneration in animal models of neurodegenerative diseases including ALS",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "un... |
NCT04082832 | CuATSM Compared With Placebo for Treatment of ALS/MND | PHASE2, PHASE3 | UNKNOWN | INTERVENTIONAL | false | Collaborative Medicinal Development Pty Limited | Multicenter, randomized, double-blind, placebo controlled study to assess the tolerabilty and efficacy of CuATSM in patients with ALS/MND. Patients will be randomized 1:1 to CuATSM or placebo for 6 x 28-day cycles (24 weeks) of treatment. | [
{
"type": "DRUG",
"name": "Cu(II)ATSM"
},
{
"type": "DRUG",
"name": "Placebos"
}
] | 2019-09-30 | https://clinicaltrials.gov/study/NCT04082832 | [
"SOD1"
] | [
{
"facility": "Macquarie University",
"city": "Macquarie",
"state": "New South Wales",
"country": "Australia",
"status": "RECRUITING",
"lat": null,
"lon": null
}
] | (415) 444 9600 | Kay.Noel@colMedDev.com | {
"criteria": "Inclusion Criteria:\n\n* signed informed consent\n* familial or sporadic ALS/MNS by Awaji-shima Consensus Recommendations\n* not taking riluzole or on stable dose of riluzole for 4 weeks prior to screening visit\n* no prior exposure to agents other than riluzole for treatment of ALS\n* adequate bone ma... | {
"compound": "Cu(II)ATSM",
"targeting_mechanism": "Copper delivery to the central nervous system that restores SOD1 copper cofactor levels and reduces oxidative stress",
"targeting_mechanism_pmid": "26826269",
"animal_results": "In SOD(G93A) mice co-expressing the Copper-Chaperone-for-SOD, CuATSM treatment res... |
NCT00753571 | Cistanche Total Glycosides for Amyotrophic Lateral Sclerosis: A Randomized Control Trial (RCT) Study Assessing Clinical Response | PHASE2 | UNKNOWN | INTERVENTIONAL | false | Peking University | This study will examine the effectiveness of Cistanche Total Glycosides(CTG) in treating patients with amyotrophic lateral sclerosis (ALS) - a fatal neurological degenerative disease that causes adult-onset, progressive motor neurons loss in the spinal cord, brain stem and motor cortex. Patients develop progressive was... | [
{
"type": "DRUG",
"name": "Cistanche Total Glycosides"
}
] | 2008-01 | https://clinicaltrials.gov/study/NCT00753571 | [
"oxidative_stress"
] | [
{
"facility": "Dongsheng Fan, MD; Liping Wang,MD",
"city": "Beijing",
"state": "Beijing Municipality",
"country": "China",
"status": "RECRUITING",
"lat": 39.9075,
"lon": 116.39723
}
] | +861082265250 | dsfan@sina.com ; chinaals@gmail.com | {
"criteria": "Inclusion Criteria:\n\n* All subjects must have a verifiable diagnosis of ALS of 0.5 to 2 years' duration.\n* The diagnosis must be supported by the Revised Criteria of the World Federation of Neurology.\n* The grades of diagnosis must be clinically definite ALS or clinically probable ALS.\n* All subje... | {
"compound": "Cistanche Total Glycosides",
"targeting_mechanism": "Antioxidant and anti-inflammatory agent targeting oxidative stress and inflammatory pathways in neurodegeneration",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"rep... |
NCT00243932 | Clinical Trial of High Dose CoQ10 in ALS | PHASE2 | COMPLETED | INTERVENTIONAL | false | Columbia University | The purpose of this study is to determine the efficacy and preferred dose of CoQ10 in individuals with ALS for a possible future phase III study. | [
{
"type": "DRUG",
"name": "coenzyme Q10"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2005-04 | https://clinicaltrials.gov/study/NCT00243932 | [
"mitochondrial_dysfunction"
] | [
{
"facility": "University of Arkansas for Medical Sciences, Department of Neurology",
"city": "Little Rock",
"state": "Arkansas",
"country": "United States",
"status": "",
"lat": 34.74648,
"lon": -92.28959
},
{
"facility": "California Pacific Medical Center",
"city": "San Fra... | {
"criteria": "Inclusion Criteria:\n\n* Clinical diagnosis of definite, probable, or laboratory-supported probable ALS\n* Negative pregnancy test for women of childbearing age and adequate birth control measures\n* Subjects must be able and willing to give informed consent and must be capable of complying with the tr... | {
"compound": "coenzyme Q10 (CoQ10)",
"targeting_mechanism": "Mitochondrial electron transport chain cofactor that enhances ATP production and reduces oxidative stress in mitochondria",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"r... | ||
NCT05189106 | Neurodegenerative Alzheimer's Disease and Amyotrophic Lateral Sclerosis (NADALS) Basket Trial | PHASE1, PHASE2 | COMPLETED | INTERVENTIONAL | false | Massachusetts General Hospital | This is an open-label, biomarker-driven basket trial of baricitinib in people with subjective cognitive disorder, mild cognitive impairment, Alzheimer's disease (AD), Amyotrophic lateral sclerosis (ALS), or asymptomatic carriers of an ALS-related gene, such as a hexanucleotide expansion in the C9ORF72 gene, with eviden... | [
{
"type": "DRUG",
"name": "Baricitinib"
}
] | 2022-12-05 | https://clinicaltrials.gov/study/NCT05189106 | [
"JAK",
"C9orf72",
"neuroinflammation"
] | [
{
"facility": "Massachusetts General Hospital - ALS Site",
"city": "Boston",
"state": "Massachusetts",
"country": "United States",
"status": "",
"lat": 42.35843,
"lon": -71.05977
},
{
"facility": "Massachusetts General Hospital - AD Site",
"city": "Charlestown",
"state": ... | {
"criteria": "Inclusion Criteria\n\nStudy participants meeting all of the following criteria will be allowed to enroll in the study:\n\n1. Must be 55-90 years old, inclusive and have one of the following:\n\n * Subjective cognitive decline(SCD)\n * Minor neurocognitive disorder(mild cognitive impairment(MCI))\n ... | {
"compound": "Baricitinib",
"targeting_mechanism": "JAK1/JAK2 inhibitor that reduces neuroinflammation and abnormal inflammatory signaling in the central nervous system",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from... | ||
NCT02750982 | Laughter Therapy Effects on Mood, Stress and Self-efficacy in People With Neurological Diseases. | NA | COMPLETED | INTERVENTIONAL | false | Brown, Theodore R., M.D., MPH | This is a prospective investigation of the effects of Laughter therapy (LT) on perceived stress, self-efficacy, mood and other wellness measures in people with the following neurological conditions: Alzheimer's disease, amyotrophic lateral sclerosis, brain injury, Huntington's Disease, multiple sclerosis, Parkinson's D... | [
{
"type": "OTHER",
"name": "Laughter Therapy"
}
] | 2016-07 | https://clinicaltrials.gov/study/NCT02750982 | [] | [
{
"facility": "Evergreen Healthcare",
"city": "Kirkland",
"state": "Washington",
"country": "United States",
"status": "",
"lat": 47.68149,
"lon": -122.20874
}
] | {
"criteria": "Inclusion Criteria:\n\n* Diagnosis based on medical record review of one of the following neurological diseases: Alzheimer's disease, amyotrophic lateral sclerosis, brain injury, Huntington's Disease, Multiple Sclerosis, Parkinson's Disease, Post-Stroke, Spinal Cord Injury.\n* Medically stable for at l... | {
"compound": "Laughter Therapy",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT05562960 | Plasmapheresis in Amyotrophic Lateral Sclerosis With Autoantibody Against NRIP | NA | COMPLETED | INTERVENTIONAL | false | National Taiwan University Hospital | Patient with amyotrophic lateral sclerosis (ALS) having anti-NRIP autoantibody showed titer-dependent detrimental Effects. Plasmapheresis might benefit this subgroup of patients via removal of anti-NRIP autoantibody | [
{
"type": "PROCEDURE",
"name": "Plasmapheresis"
}
] | 2023-05-01 | https://clinicaltrials.gov/study/NCT05562960 | [
"NRIP"
] | [
{
"facility": "National Taiwan University Hospital",
"city": "Taipei",
"state": "",
"country": "Taiwan",
"status": "",
"lat": 25.05306,
"lon": 121.52639
}
] | {
"criteria": "Inclusion Criteria:\n\n1. Patients with amyotrophic lateral sclerosis (ALS) at the age more than 20 years and having plasma anti-NRIP autoantibody.\n2. Agree to receive plasmapheresis intervention.\n3. Agree to participate in the trial and receive serial examinations and follow up.\n\nExclusion Criteri... | {
"compound": "Plasmapheresis",
"targeting_mechanism": "Removal of anti-NRIP autoantibodies to reduce titer-dependent detrimental effects in ALS patients.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT05903690 | Safety and Tolerance of RAG-17 in Amyotrophic Lateral Sclerosis Patients With SOD1 Gene Mutation | EARLY_PHASE1 | COMPLETED | INTERVENTIONAL | false | Beijing Tiantan Hospital | The goal of this clinical trial is to evaluate the safety, tolerability and pharmacokinetics of RAG-17 in adult amyotrophic lateral sclerosis (ALS) patients with SOD1 mutation. Patients will receive drug treamtent via dose escalation which ranging from minimum of 60 mg to the maximum tolerated dose (MTD), after reachin... | [
{
"type": "DRUG",
"name": "RAG-17"
}
] | 2023-05-24 | https://clinicaltrials.gov/study/NCT05903690 | [
"SOD1"
] | [
{
"facility": "Beijing Tiantan Hospital",
"city": "Beijing",
"state": "",
"country": "China",
"status": "",
"lat": 39.9075,
"lon": 116.39723
}
] | {
"criteria": "Inclusion Criteria:\n\n* Patients who are judged by professional medical staff to still be able to carry out the clinical trial project cycle;\n* 18 years old ≤ age ≤ 75 years old, males or females;\n* ALS patients with confirmed SOD1 gene mutations document (known SOD1 mutation sites and related disea... | {
"compound": "RAG-17",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT02437110 | HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS) | PHASE1 | COMPLETED | INTERVENTIONAL | false | National Institute of Neurological Disorders and Stroke (NINDS) | Background:
Some people with Amyotrophic Lateral Sclerosis (ALS) have a high level of the virus HERV-K in their blood. Researchers do not think this virus causes ALS. But they don t know why some people with ALS have a high level of it. They want to know if HERV-K can be suppressed by drugs that are used to treat HIV ... | [
{
"type": "DRUG",
"name": "Darunavir"
},
{
"type": "DRUG",
"name": "Ritonavir"
},
{
"type": "DRUG",
"name": "Dolutegravir"
},
{
"type": "DRUG",
"name": "Tenofovir alafenamide (TAF)"
}
] | 2019-04-01 | https://clinicaltrials.gov/study/NCT02437110 | [
"herv_k"
] | [
{
"facility": "National Institutes of Health Clinical Center",
"city": "Bethesda",
"state": "Maryland",
"country": "United States",
"status": "",
"lat": 38.98067,
"lon": -77.10026
}
] | {
"criteria": "INCLUSION CRITERIA:\n\nSubjects must meet all of the following inclusion criteria to be eligible to participate in this study:\n\nAge 18 years or older at the time of the screening visit.\n\nAble to provide informed consent and comply with study procedures.\n\nALS diagnosed as probable, laboratory-supp... | {
"compound": "Darunavir, Ritonavir, Dolutegravir, Tenofovir alafenamide (TAF)",
"targeting_mechanism": "Suppression of human endogenous retrovirus K (HERV-K) using antiretroviral therapy.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",... | ||
NCT03455309 | Evaluation of NDV-3A Vaccine in Preventing S. Aureus Colonization | PHASE2 | COMPLETED | INTERVENTIONAL | false | NovaDigm Therapeutics, Inc. | The proposed study aims to further evaluate the safety and immunogenicity of a candidate S. aureus vaccine NDV-3A, as well as its efficacy against acquisition of S. aureus | [
{
"type": "BIOLOGICAL",
"name": "NDV-3A"
},
{
"type": "BIOLOGICAL",
"name": "Placebo"
}
] | 2018-01-30 | https://clinicaltrials.gov/study/NCT03455309 | [] | [
{
"facility": "Fort Benning",
"city": "Fort Benning",
"state": "Georgia",
"country": "United States",
"status": "",
"lat": 32.35237,
"lon": -84.96882
}
] | {
"criteria": "Inclusion Criteria:\n\n* Active duty, male subject, 17-35 years of age, inclusive, at the time of screening.\n* Assigned to one of the selected companies/battalions\n* Informed of the nature of the study and has agreed to and is able to read, review, and sign the informed consent document prior to scre... | {
"compound": "NDV-3A",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT04577404 | Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS) | PHASE3 | COMPLETED | INTERVENTIONAL | false | Shionogi | This is a Phase 3, international, multicenter, open-label, long-term extension study. The primary objective of this study is to evaluate the long-term safety and tolerability of oral edaravone in subjects with Amyotrophic Lateral Sclerosis (ALS) for up to 96 weeks. | [
{
"type": "DRUG",
"name": "MT-1186"
}
] | 2020-10-29 | https://clinicaltrials.gov/study/NCT04577404 | [
"oxidative_stress"
] | [
{
"facility": "St. Joseph's Hospital and Medical Center (SJHMC) - Barrow Neurological Institute (BNI) - The Gregory W. Fulton ALS and Neuromuscular Disease Center",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
},
... | {
"criteria": "Inclusion Criteria:\n\n1. Subjects must provide signed and dated informed consent form (ICF) to participate in the study. Subjects must be able (in the judgment of the Investigator) to understand the nature of the study and all risks involved with participation in the study.\n2. Subjects must be willin... | {
"compound": "MT-1186",
"targeting_mechanism": "Oral edaravone acts as a free radical scavenger to reduce oxidative stress in motor neurons.",
"targeting_mechanism_pmid": "38473944",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT02870634 | Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND | PHASE1 | COMPLETED | INTERVENTIONAL | false | Collaborative Medicinal Development Pty Limited | Multicenter, open-label , single and multiple dose-escalation and pharmacokinetic study | [
{
"type": "DRUG",
"name": "Cu(II)ATSM"
}
] | 2016-11-16 | https://clinicaltrials.gov/study/NCT02870634 | [
"SOD1"
] | [
{
"facility": "Macquarie University",
"city": "Sydenham",
"state": "New South Wales",
"country": "Australia",
"status": "",
"lat": -33.91669,
"lon": 151.16798
},
{
"facility": "Calvary Health Care Bethlehem",
"city": "Caulfield",
"state": "Victoria",
"country": "Austr... | {
"criteria": "Inclusion Criteria:\n\n* Signed informed consent prior to initiation of any study-specific procedures;\n* Familial or sporadic ALS/MND defined as clinically possible, probable, or definite by Awaji-shima Consensus Recommendations;\n* First ALS/MND symptoms occurred no more than 2 years prior to screeni... | {
"compound": "Cu(II)ATSM",
"targeting_mechanism": "Cu(II)ATSM delivers copper to the central nervous system to restore copper-dependent SOD1 function and antioxidant defense in motor neurons.",
"targeting_mechanism_pmid": "26826269",
"animal_results": "CuATSM treatment rescued early death in SOD(G93A) mice co-... | ||
NCT06849609 | A Study to Evaluate the Tolerability, Safety and Efficacy of VGN-R13 in Patients with ALS | EARLY_PHASE1 | RECRUITING | INTERVENTIONAL | false | Hong Chen | The purpose of this trial is to evaluate safety and efficacy of intrathecal delivery of VGN-R13 as a treatment of Amyotrophic Lateral Sclerosis (ALS). | [
{
"type": "BIOLOGICAL",
"name": "VGN-R13"
}
] | 2025-01-16 | https://clinicaltrials.gov/study/NCT06849609 | [
"motor_neuron_degeneration"
] | [
{
"facility": "TongJi Hospital",
"city": "Wuhan",
"state": "Hubei",
"country": "China",
"status": "RECRUITING",
"lat": 30.58333,
"lon": 114.26667
}
] | 13296508243 | chenhong1129@hotmail.com | {
"criteria": "key Inclusion Criteria:\n\n1. Fully understand the purpose and risks of the study and voluntarily provide a signed and dated informed consent form.\n2. Aged ≥18 years, male or female;\n3. A diagnosis of ALS according to the World Federation of Neurology El Escorial criteria (revised according to the Ai... | {
"compound": "VGN-R13",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT02193893 | Biological Treatment of Amyotrophic Lateral Sclerosis | PHASE1 | UNKNOWN | INTERVENTIONAL | false | Pomeranian Medical University Szczecin | The purpose of this study is to test the safety and effectiveness of an autologous bone marrow-derived stem/progenitor cells infusion in the subjects with diagnosed amyotrophic lateral sclerosis. | [
{
"type": "OTHER",
"name": "Biological: Cell-based therapeutics"
},
{
"type": "OTHER",
"name": "Symptomatic treatment of ALS"
}
] | 2010-01 | https://clinicaltrials.gov/study/NCT02193893 | [
"neuroprotection"
] | [
{
"facility": "Department of Neurology of Pomeranian Medical University in Szczecin",
"city": "Szczecin",
"state": "Poland",
"country": "Poland",
"status": "",
"lat": 53.42894,
"lon": 14.55302
}
] | {
"criteria": "Inclusion Criteria:\n\n* diagnosis of the ALS disease before the cell transplantation (diagnose established following the El Escorial criteria for definite ALS)\n* good understanding of the protocol and willingness to consent\n* patient is mentally intact and psychologically stable\n* signed informed c... | {
"compound": "Autologous bone marrow-derived stem/progenitor cells",
"targeting_mechanism": "Stem cells can differentiate into support cells such as astrocytes, oligodendrocytes or microglia, which may benefit degenerating motor neurons by producing growth factors and anti-inflammatory cytokines, providing nutrien... | ||
NCT00072709 | Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | COMPLETED | INTERVENTIONAL | false | Novartis Pharmaceuticals | This is a global multicenter study designed to evaluate the safety and clinical effects of 4 oral doses of TCH346 (1.0, 2.5, 7.5, and 15 mg) compared to placebo in patients with mild or mild to moderate stages of ALS. The study consists of 3 phases: screening (up to 2 weeks), run-in (16 weeks), and a double-blind treat... | [
{
"type": "DRUG",
"name": "TCH346"
}
] | 2003-09 | https://clinicaltrials.gov/study/NCT00072709 | [
"mitochondrial_dysfunction"
] | [
{
"facility": "Novartis USA",
"city": "East Hanover",
"state": "New Jersey",
"country": "United States",
"status": "",
"lat": 40.8201,
"lon": -74.36487
},
{
"facility": "Novartis Belgium",
"city": "Vilvoorde",
"state": "",
"country": "Belgium",
"status": "",
"... | {
"criteria": "Inclusion criteria:\n\n* clinical diagnosis of laboratory-supported probable, probable, or definite ALS;\n* sporadic or familial ALS;\n* ALS symptom onset for no more than 3 yrs at study entry;\n* FVC equal to or more than 70%;\n* patients who are either riluzole naive or patients who are receiving con... | {
"compound": "TCH346",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT03324399 | A Study of Protein Metabolism, Microbiome and Investigational Probiotic Use in Patients With ALS | NA | COMPLETED | INTERVENTIONAL | false | Avera McKennan Hospital & University Health Center | ALS, also known as "Lou Gehrig's" disease, is a neurodegenerative disease which is fatal. Treatment for ALS is limited and currently consists of primary symptom relief or support. In addition, time from diagnosis to death averages 3-5 years. New Biotic, LLC has submitted an Orphan Drug Designation Application for an in... | [
{
"type": "DIETARY_SUPPLEMENT",
"name": "probiotic"
}
] | 2017-06-01 | https://clinicaltrials.gov/study/NCT03324399 | [
"neuroinflammation"
] | [
{
"facility": "Avera Medical Group Palliative Medicine Sioux Falls",
"city": "Sioux Falls",
"state": "South Dakota",
"country": "United States",
"status": "",
"lat": 43.54369,
"lon": -96.72796
}
] | {
"criteria": "Inclusion Criteria:\n\n* Diagnosis of sporadic ALS, definite or probable disease,-revised El Escorial criteria\n* Patient must be able to understand the purpose and procedures of the study, sign informed consent and comply with requirements of the protocol.\n* Age 18 and older.\n* Normal serum Magnesiu... | {
"compound": "probiotic",
"targeting_mechanism": "Modulation of gut microbiota composition to reduce neuroinflammation and support motor neuron function through alterations in microbial dysbiosis associated with ALS pathogenesis.",
"targeting_mechanism_pmid": "28129947",
"animal_results": "Unknown",
"animal_... | ||
NCT05880563 | Investigation of Cannabinoid 2-receptor Expression in the Brain and Spine of ALS-patients Compared to Healthy Controls With PET (18F-RoSMALS) | PHASE1 | NOT_YET_RECRUITING | INTERVENTIONAL | false | Markus Weber | This clinical trial is a phase 1 study in which investigations with the weakly radioactive substance \[18F\]-RoSMA-18-d6 are being carried out for the first time.
This radiolabeled substance will be used to study a specific protein in the brain and spinal cord of patients with ALS and healthy individuals. This particu... | [
{
"type": "DRUG",
"name": "[18F]-RoSMA-18-d6"
}
] | 2023-08 | https://clinicaltrials.gov/study/NCT05880563 | [
"CNR2"
] | [
{
"facility": "Muskelzentrum/ALS-Clinic, Kantonsspital St. Gallen",
"city": "Sankt Gallen",
"state": "",
"country": "Switzerland",
"status": "",
"lat": 47.42391,
"lon": 9.37477
}
] | {
"criteria": "Inclusion Criteria \\_ALS-patients:\n\n* Age ≥18 years\n* Able to provide written informed consent prior to study participation\n* Body weight of ≥ 50 kg and a body mass index (BMI) between 19-30 kg/m2\n* Vital signs measured after three minutes resting in the supine position must be within the followi... | {
"compound": "[18F]-RoSMA-18-d6",
"targeting_mechanism": "A radiolabeled PET tracer that binds to cannabinoid type 2 receptors in the brain and spinal cord to assess their expression as a biomarker in ALS pathophysiology.",
"targeting_mechanism_pmid": "",
"animal_results": "Unknown",
"animal_results_pmid": "... | ||
NCT04332198 | Neurobiological and Immunological Mechanisms of Dyspnea in ALS (BIOPNEA) | NA | UNKNOWN | INTERVENTIONAL | false | Association pour le Développement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil | Dyspnea; subjective experience of respiratory discomfort; which produces negative emotional experience, is the most common symptom of patients afflicted with chronic respiratory failure and its treatments are limited. Amyotrophic Lateral Sclerosis (ALS) related - dyspnea, due to diaphragmatic dysfunction, is similar to... | [
{
"type": "OTHER",
"name": "biological test"
}
] | 2023-07 | https://clinicaltrials.gov/study/NCT04332198 | [] | [] | {
"criteria": "Inclusion Criteria:\n\n\\- Patients with chronic respiratory failure with diaphragmatic dysfunction linked to amyotrophic lateral sclerosis and requiring long-term NIV\n\nExclusion Criteria:\n\n* Other respiratory disease (COPD, asthma, obstructive sleep apnea)\n* Alcohol or psychotropic drug the lasts... | {
"compound": "biological test",
"targeting_mechanism": "Unknown",
"targeting_mechanism_pmid": "",
"animal_results": "Unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT03505021 | Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS | PHASE3 | COMPLETED | INTERVENTIONAL | false | Orion Corporation, Orion Pharma | This study will evaluate whether prolonged oral levosimendan can preserve respiratory function more effectively than placebo, resulting in better patient functionality as measured by the ALSFRS-R scale. In this randomized, double-blind, placebo-controlled, parallel-group, multicenter study, subjects are allocated in a ... | [
{
"type": "DRUG",
"name": "Levosimendan"
},
{
"type": "DRUG",
"name": "Placebo for levosimendan"
}
] | 2018-06-21 | https://clinicaltrials.gov/study/NCT03505021 | [
"cardiac_muscle_function"
] | [
{
"facility": "Phoenix Neurological Associates",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "Neuromuscular Research Center and Neuromuscular Clinic of Arizona",
"city": "Phoenix",
"s... | {
"criteria": "Inclusion Criteria:\n\n* Written or verbal informed consent (IC) for participation in the study\n* Male or female subjects with diagnosis of laboratory supported probable, probable or definite ALS according to El Escorial revised criteria. Full electromyogram (EMG) report available consistent with ALS ... | {
"compound": "Levosimendag",
"targeting_mechanism": "Unknown",
"targeting_mechanism_pmid": "",
"animal_results": "Unknown",
"animal_results_pmid": "",
"repurposed_from": "Unknown",
"repurposed_from_pmid": ""
} | ||
NCT06199284 | Atalante Exoskeleton in the Rehabilitation of Patients With Amyotrophic Lateral Sclerosis | NA | SUSPENDED | INTERVENTIONAL | false | Institut de Recherche sur la Moelle épinière et l'Encéphale | Using a MRI gait motor imagery paradigm in ALS patients in order to study how ALS affects the function of the central neural networks involved in gait function, we showed a reorganization of the motor networks that represents a compensatory response to the dysfunction of the networks involved in gait function. Our main... | [
{
"type": "DEVICE",
"name": "Atalante exoskeleton"
}
] | 2024-01-31 | https://clinicaltrials.gov/study/NCT06199284 | [] | [
{
"facility": "Station Debout",
"city": "Paris",
"state": "",
"country": "France",
"status": "",
"lat": 48.85341,
"lon": 2.3488
},
{
"facility": "Hôpital Pitié-Salpêtrière",
"city": "Paris",
"state": "",
"country": "France",
"status": "",
"lat": 48.85341,
... | {
"criteria": "Inclusion Criteria:\n\n* Patients with amyotrophic lateral sclerosis (defined according to the El Escorial criteria: possible, probable or definite), at the time of diagnosis\n* Male or female, between 18 and 70 years of age\n* Slowly and moderately evolving patients ∆ ALS Progression rate (FS) ≤ 1.11 ... | {
"compound": "Atalante exoskeleton",
"targeting_mechanism": "A robotic exoskeleton that provides proprioceptive input to engage motor cortex compensatory network reorganization and improve gait function through motor learning.",
"targeting_mechanism_pmid": "",
"animal_results": "Unknown",
"animal_results_pmi... | ||
NCT07543367 | INdependence Through Endovascular Neuroprosthetic Technology (INTENT): an Early Feasibility Study | NA | RECRUITING | INTERVENTIONAL | false | Synchron, Inc. | INdependence Through Endovascular Neuroprosthetic Technology (INTENT): an Early Feasibility Study | [
{
"type": "DEVICE",
"name": "Stentrode"
}
] | 2026-04 | https://clinicaltrials.gov/study/NCT07543367 | [] | [
{
"facility": "Mayo Clinic",
"city": "Jacksonville",
"state": "Florida",
"country": "United States",
"status": "RECRUITING",
"lat": 30.33218,
"lon": -81.65565
},
{
"facility": "University of Buffalo Neurosurgery",
"city": "Buffalo",
"state": "New York",
"country": "Un... | {
"criteria": "Inclusion Criteria:\n\n* Able to provide informed consent to participate in the study.\n* Diagnosis of ALS, with bilateral upper-limb paresis.\n* ALS must be refractory to treatment and have been present for a minimum of six months.\n* Aged 22 years or older.\n* Life expectancy greater than 12 months p... | {
"compound": "Stentrode",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT04066244 | Study of Safety and Proof of the Mechanism of BLZ945 in ALS Patients | PHASE2 | TERMINATED | INTERVENTIONAL | false | Novartis Pharmaceuticals | It was an open label study to evaluate safety, tolerability and brain microglia response in participants with Amyotrophic Lateral Sclerosis (ALS) following multiple doses of BLZ945. | [
{
"type": "DRUG",
"name": "BLZ945"
}
] | 2019-12-30 | https://clinicaltrials.gov/study/NCT04066244 | [
"CSF1R"
] | [
{
"facility": "Yale University School of Medicine",
"city": "New Haven",
"state": "Connecticut",
"country": "United States",
"status": "",
"lat": 41.30815,
"lon": -72.92816
},
{
"facility": "Massachusetts General Hospital",
"city": "Boston",
"state": "Massachusetts",
... | {
"criteria": "Inclusion Criteria:\n\n* Able to communicate well with the investigator, to understand and comply with the study visits and procedures of the study\n* Written informed consent must be obtained before any assessment is performed.\n* Male and female participants who are 18 years old or older at screening... | {
"compound": "BLZ945",
"targeting_mechanism": "A CSF1R inhibitor that targets microglial activation in the central nervous system.",
"targeting_mechanism_pmid": "",
"animal_results": "In SOD1G93A mice, the temporal evolution of the immune response and microglial activation is associated with disease progressio... | ||
NCT03338114 | Study to Evaluate the Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Upper or Lower Extremity Muscles Most Affected in Subjects With ALS | PHASE1, PHASE2 | WITHDRAWN | INTERVENTIONAL | false | Flex Pharma, Inc. | The FLX-787-106 study will determine how well FLX-787-ODT works to reduce fasciculations in patients with Amyotrophic Lateral Sclerosis (ALS). The study will measure how often fasciculations occur, and monitor any side effects that might develop while taking the investigational product. Participants will be assessed be... | [
{
"type": "DRUG",
"name": "FLX-787-ODT (orally disintigrating tablet)"
}
] | 2017-11 | https://clinicaltrials.gov/study/NCT03338114 | [
"fasciculation_neuromuscular_function"
] | [
{
"facility": "Wake Forest University Health Sciences",
"city": "Winston-Salem",
"state": "North Carolina",
"country": "United States",
"status": "",
"lat": 36.09986,
"lon": -80.24422
}
] | {
"criteria": "Inclusion Criteria:\n\n* Documented diagnosis of ALS diagnosis of less than 3 years.\n* Expected survival \\> 6 months\n* Frequent fasciculations noted during clinical examination of any single muscle (\\>6 visible fasciculations per minute) observed in Part I\n* Normal oral cavity exam at screening\n*... | {
"compound": "FLX-787-ODT",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT01730716 | Dose Escalation and Safety Study of Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis | PHASE2 | UNKNOWN | INTERVENTIONAL | false | Neuralstem Inc. | The study is to determine the feasibility, safety, toxicity, and maximum tolerated (safe) dose of human spinal derived neural stem cell transplantation for the treatment of Amyotrophic Lateral Sclerosis (ALS). | [
{
"type": "DEVICE",
"name": "Human spinal cord stem cell implantation"
}
] | 2013-05 | https://clinicaltrials.gov/study/NCT01730716 | [] | [
{
"facility": "Emory University",
"city": "Atlanta",
"state": "Georgia",
"country": "United States",
"status": "",
"lat": 33.749,
"lon": -84.38798
},
{
"facility": "Massachusetts General Hospital",
"city": "Boston",
"state": "Massachusetts",
"country": "United States"... | {
"criteria": "Inclusion Criteria:\n\n1. Have the ability to understand the requirements of the study, provide written informed consent, understand and provide written authorization for the use and disclosure of Protected Health Information (PHI) \\[per Health Insurance Portability and Accountability Act (HIPAA) Priv... | {
"compound": "Human spinal cord stem cell implantation",
"targeting_mechanism": "Human spinal cord-derived neural stem cells that can differentiate into motor neurons and support cells (astrocytes, oligodendrocytes) to provide trophic support through growth factors and anti-inflammatory cytokines.",
"targeting_m... | ||
NCT02164253 | Focal Accumulation of Iron in Cerebral Regions in Early ALS (Amyotrophic Lateral Sclerosis) Patients | PHASE2 | COMPLETED | INTERVENTIONAL | false | University Hospital, Lille | The FAIR-ALS study is to investigate the safety and efficacy of a scavenger treatment of iron deferiprone, which would reduce the brain iron to limit the development of amyotrophic lateral sclerosis.
It has been shown an excess of iron in the central nervous system carrying a sporadic ALS patients. Iron overload assoc... | [
{
"type": "DRUG",
"name": "Deferiprone"
}
] | 2013-09 | https://clinicaltrials.gov/study/NCT02164253 | [
"iron_homeostasis"
] | [
{
"facility": "Hôpital Roger Salengro, CHRU de Lille",
"city": "Lille",
"state": "",
"country": "France",
"status": "",
"lat": 50.63391,
"lon": 3.05512
}
] | {
"criteria": "Inclusion Criteria:\n\n* Amyotrophic lateral sclerosis defined in accordance to the El Escorial criteria (possible, probable or defined)\n* 18 to 85 years old patient, male or female\n* Patient with social security cover\n\nExclusion Criteria:\n\n* Achieved respiratory defined by a FVC \\<70%\n* Evolut... | {
"compound": "Deferiprone",
"targeting_mechanism": "An iron chelator that scavenges excess iron in the central nervous system to reduce iron-associated oxidative stress and motor neuron degeneration.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from"... | ||
NCT04575727 | Exploratory Evaluation of [11C]MPC6827 | EARLY_PHASE1 | COMPLETED | INTERVENTIONAL | false | Columbia University | This is a phase 0 study that will enable an assessment of biodistribution and estimation of absorbed dose in humans based on data collected from five healthy volunteers, which is typically the minimum number required by the FDA for first-in-human studies to assess dosimetry of a new tracer. The evaluation of the brain ... | [
{
"type": "DRUG",
"name": "[11C]MPC6827"
}
] | 2021-01-08 | https://clinicaltrials.gov/study/NCT04575727 | [] | [
{
"facility": "Cuimc / Nyp",
"city": "New York",
"state": "New York",
"country": "United States",
"status": "",
"lat": 40.71427,
"lon": -74.00597
}
] | {
"criteria": "Inclusion Criteria (Healthy Volunteers)\n\n1. All volunteers must be 18 years of age or older, able to read, understand and voluntarily sign and informed consent document.\n2. Volunteers must have no current medical history of brain disease\n3. Negative pregnancy test if female of childbearing potentia... | {
"compound": "[11C]MPC6827",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT03039673 | MIROCALS: Modifying Immune Response and OutComes in ALS | PHASE2 | COMPLETED | INTERVENTIONAL | false | Centre Hospitalier Universitaire de Nīmes | MIROCALS is a phase II study of ld-IL-2 as a therapeutic agent for ALS. A randomized (1:1), placebo-controlled, double-blind, parallel group trial will be carried out to assess ld-IL-2 safety and clinical efficacy on survival and functional decline in newly diagnosed ALS patients treated for 18 months. Randomization wi... | [
{
"type": "DRUG",
"name": "Riluzole"
},
{
"type": "DRUG",
"name": "IL-2"
},
{
"type": "DRUG",
"name": "5% glucose water solution"
}
] | 2017-06-19 | https://clinicaltrials.gov/study/NCT03039673 | [
"IL-2"
] | [
{
"facility": "CHRU de Lille - Hôpital Roger Salengro",
"city": "Lille",
"state": "",
"country": "France",
"status": "",
"lat": 50.63391,
"lon": 3.05512
},
{
"facility": "CHU de Limoges - Hôpital Dupuytren",
"city": "Limoges",
"state": "",
"country": "France",
"st... | {
"criteria": "Main Inclusion criteria\n\n* Patient is 18 years old and less than 76 years old\n* Possible, Probable, Probable laboratory-supported or Definite ALS as defined by El Escorial Revised ALS diagnostic criteria\n* Disease duration \\<= 24 months\n* Slow Vital capacity \\>= 70% of normal\n* No prior or pres... | {
"compound": "ld-IL-2",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT03876002 | Evaluation of Microglial Activation in ALS With [18F]PBR06 (Peripheral Benzodiazepine Receptor-06) PET | PHASE1 | COMPLETED | INTERVENTIONAL | false | Molecular NeuroImaging | The overall goal of this protocol is to evaluate microglial activation in the brain using \[18F\]PBR06 in patients with amyotrophic lateral sclerosis (ALS). | [
{
"type": "DRUG",
"name": "[18F]PBR06"
}
] | 2016-06-28 | https://clinicaltrials.gov/study/NCT03876002 | [
"neuroinflammation"
] | [
{
"facility": "Molecular NeuroImaging, LLC",
"city": "New Haven",
"state": "Connecticut",
"country": "United States",
"status": "",
"lat": 41.30815,
"lon": -72.92816
}
] | {
"criteria": "Inclusion Criteria (for all subjects):\n\n* Written informed consent must be obtained before any assessment is performed.\n* Provide signed and dated written informed consent.\n* Female subjects must be documented by medical records or physician's note to be either surgically sterile (by means of hyste... | {
"compound": "[18F]PBR06",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT00600873 | R(+)PPX High Dose Treatment of ALS | PHASE1, PHASE2 | COMPLETED | INTERVENTIONAL | false | Bennett, James P., Jr., M.D., Ph.D. | R(+)pramipexole is administered in escalating doses to patients with early ALS. Plasma and spinal fluid levels of R(+)PPX are monitored, in addition to biochemical markers of oxidative stress. | [
{
"type": "DRUG",
"name": "R(+) pramipexole dihydrochloride monohydrate"
}
] | 2007-08 | https://clinicaltrials.gov/study/NCT00600873 | [
"oxidative_stress"
] | [
{
"facility": "University of Virginia",
"city": "Charlottesville",
"state": "Virginia",
"country": "United States",
"status": "",
"lat": 38.02931,
"lon": -78.47668
}
] | {
"criteria": "Inclusion Criteria:\n\n* definite ALS no prior exposure to R(+)PPX\n\nExclusion Criteria:\n\n* ALSFRS at baseline \\<40 FVC at baseline \\<70%",
"sex": "ALL",
"min_age": "30 Years",
"max_age": "80 Years",
"healthy_volunteers": false,
"std_ages": [
"ADULT",
"OLDER_ADULT"
]
} | {
"compound": "R(+) pramipexole dihydrochloride monohydrate",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT03618966 | Neuromuscular Magnetic Stimulation in ALS Patients | PHASE2 | COMPLETED | INTERVENTIONAL | false | University of Roma La Sapienza | Aim of the study is to verify whether neuromuscular magnetic stimulation can improve muscle function in spinal-onset Amyotrophic Lateral Sclerosis (ALS) patients. | [
{
"type": "DEVICE",
"name": "Neuromuscular magnetic stimulation (NMMS)"
}
] | 2014-11-01 | https://clinicaltrials.gov/study/NCT03618966 | [] | [] | {
"criteria": "Inclusion Criteria:\n\n* diagnosis of probable or definite ALS with spinal-onset\n* right-handed patients\n* a bilateral symmetric muscular deficit in flexor carpi radialis muscle or flexor digitorum profundus muscle (defined by a MRC Muscle Scale score of 3-4/5)\n\nExclusion Criteria:\n\n* history of ... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT07703462 | Personalized Antisense Oligonucleotide Therapy for a Participant With TARDBP ALS | PHASE1, PHASE2 | ENROLLING_BY_INVITATION | INTERVENTIONAL | false | n-Lorem Foundation | This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with amyotrophic lateral sclerosis (ALS) due to a pathogenic variant in TARDBP. | [
{
"type": "DRUG",
"name": "nL-TARDB-002"
}
] | 2026-12 | https://clinicaltrials.gov/study/NCT07703462 | [
"TARDBP"
] | [
{
"facility": "Jefferson Health",
"city": "Philadelphia",
"state": "Pennsylvania",
"country": "United States",
"status": "",
"lat": 39.95238,
"lon": -75.16362
}
] | {
"criteria": "Inclusion Criteria:\n\n* Informed consent/assent provided by the participant (when appropriate), and/or participants parent(s) or legally authorized representative(s)\n* Ability to travel to the study site and adhere to study-related follow-up examinations and/or procedures and provide access to partic... | {
"compound": "nL-TARDB-002",
"targeting_mechanism": "Antisense oligonucleotide (ASO) designed to target pathogenic variants in TARDBP to suppress mutant TDP-43 expression in motor neurons.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repu... | ||
NCT01494480 | The Clinical Trial on the Use of Umbilical Cord Mesenchymal Stem Cells in Amyotrophic Lateral Sclerosis | PHASE2 | UNKNOWN | INTERVENTIONAL | false | General Hospital of Chinese Armed Police Forces | Patients with Amyotrophic Lateral Sclerosis (ALS) typically endure a progressive paralysis due to the continued loss of motoneurons that leads them to death in less than 5 years. No treatment has changed its natural history. Intrathecal injection of umbilical cord mesenchymal stem cells can secret trophic factors that ... | [
{
"type": "PROCEDURE",
"name": "stem cell transplantation"
}
] | 2012-03 | https://clinicaltrials.gov/study/NCT01494480 | [
"neuroprotection_motor_neuron_survival"
] | [
{
"facility": "Yihua An",
"city": "Beijing",
"state": "",
"country": "China",
"status": "",
"lat": 39.9075,
"lon": 116.39723
}
] | {
"criteria": "Inclusion Criteria:\n\n* Diagnose established following the World Federation of Neurology criteria\n* More than 6 and less than 36 months of evolution of the disease\n* Medullar onset of the disease\n* More than 20 and less than 65 years old\n* Forced Vital Capacity equal or superior to 50%\n* Total ti... | {
"compound": "umbilical cord mesenchymal stem cells",
"targeting_mechanism": "Stem cell transplantation to secrete trophic factors that preserve motor neuron function and provide neuroprotection.",
"targeting_mechanism_pmid": "",
"animal_results": "Neural progenitor cells transduced with GDNF (glial cell line-... | ||
NCT04686110 | Analysis of Capillary Retinal and Papillary Vascularization in Patients With Amyotrophic Lateral Sclerosis - CAPISLA | NA | UNKNOWN | INTERVENTIONAL | false | University Hospital, Angers | Amyotrophic Lateral Sclerosis, or Charcot's disease, is a neurodegenerative disease affecting motor neurons. The disease affects between 5 and 10 people per 100,000 in the world, nearly 7,000 patients are affected in France. The only therapeutic treatment available to date in France is riluzole, which slows the progres... | [
{
"type": "OTHER",
"name": "angiographic optical coherence tomography"
}
] | 2021-02-12 | https://clinicaltrials.gov/study/NCT04686110 | [] | [
{
"facility": "CHU Angers",
"city": "Angers",
"state": "",
"country": "France",
"status": "RECRUITING",
"lat": 47.47156,
"lon": -0.55202
}
] | 0241353637 | jeanne.muller@chu-angers.fr | {
"criteria": "Inclusion Criteria:\n\nPatient Amyotrophic Lateral Sclerosis :\n\n* Patient diagnosed with bulbar or spinal ALS defined according to El Escorial criteria (probable or certain)\n* Hospitalized in a day hospital at the Angers University Hospital as part of his usual follow-up\n\nControl subject :\n\n* Su... | {
"compound": "unknown",
"targeting_mechanism": "This is a diagnostic imaging study using angiographic optical coherence tomography to analyze retinal and papillary vascularization as a biomarker for ALS; it is not a therapeutic intervention trial.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
... |
NCT02236897 | PET Imaging in ALS Patients | NA | COMPLETED | INTERVENTIONAL | false | Johns Hopkins University | This is a pilot study to evaluate a potential imaging biomarker for aiding diagnosis and monitoring progression of ALS, based on a well established basic science pathway, published human autopsy data, preliminary data in ALS mutant mice, and our recently published data using brain PET scans to image the metabotropic gl... | [
{
"type": "OTHER",
"name": "PET Scanning"
}
] | 2013-08 | https://clinicaltrials.gov/study/NCT02236897 | [
"MGluR5"
] | [
{
"facility": "Johns Hopkins University",
"city": "Baltimore",
"state": "Maryland",
"country": "United States",
"status": "",
"lat": 39.29038,
"lon": -76.61219
}
] | {
"criteria": "Inclusion Criteria:\n\n* Male or female ALS patients, ranging in age from 18-80.\n* Must meet El Escorial Criteria for Probable or Definite ALS.\n* Disease duration \\>1 year, but \\<3 years.\n* Weakness in at least two extremities.\n* Forced vital capacity less than 80% and greater than 50%.\n\nExclus... | {
"compound": "unknown",
"targeting_mechanism": "This is a diagnostic imaging study using PET scanning to image metabotropic glutamate receptor type 5 (mGluR5) as a potential biomarker for ALS diagnosis and disease progression monitoring; it is not a therapeutic intervention trial.",
"targeting_mechanism_pmid": "... | ||
NCT01786174 | Gilenya in Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | COMPLETED | INTERVENTIONAL | false | Massachusetts General Hospital | The purpose of this study is to determine whether Gilenya, also known as fingolimod, is safe and tolerable in patients with Amyotrophic Lateral Sclerosis (ALS). | [
{
"type": "DRUG",
"name": "Gilenya"
},
{
"type": "OTHER",
"name": "Placebo"
}
] | 2013-08 | https://clinicaltrials.gov/study/NCT01786174 | [
"S1P1"
] | [
{
"facility": "University of California, Irvine",
"city": "Orange",
"state": "California",
"country": "United States",
"status": "",
"lat": 33.78779,
"lon": -117.85311
},
{
"facility": "Georgia Regents University",
"city": "Augusta",
"state": "Georgia",
"country": "Un... | {
"criteria": "Inclusion Criteria:\n\n1. Age 18 years or older.\n2. Sporadic or familial ALS diagnosed as possible, laboratory-supported probable, probable, or definite as defined by revised El Escorial criteria (Appendix 1).\n3. Onset of weakness or spasticity due to ALS ≤ 2 years (24 months) prior to Baseline Visit... | {
"compound": "Gilenya (fingolimod)",
"targeting_mechanism": "Sphingosine 1-phosphate receptor modulator that crosses the blood-brain barrier and modulates immune cell trafficking to reduce neuroinflammation in ALS.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"r... | ||
NCT04840823 | Enoxacin for Amyotrophic Lateral Sclerosis (ALS) | PHASE1, PHASE2 | COMPLETED | INTERVENTIONAL | false | McGill University | The study will assess the safety of the drug enoxacin at specific dose levels in adults with ALS. | [
{
"type": "DRUG",
"name": "Enoxacin"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2021-03-26 | https://clinicaltrials.gov/study/NCT04840823 | [
"PINK1"
] | [
{
"facility": "Montreal Neurological Institute-Hospital",
"city": "Montreal",
"state": "Quebec",
"country": "Canada",
"status": "",
"lat": 45.50884,
"lon": -73.58781
}
] | {
"criteria": "Inclusion Criteria:\n\n* Diagnosis of familial or sporadic ALS\n* FVC of ≥ 50 percent predicted\n* If female, is not breastfeeding and is not pregnant\n* Has been on a stable dose of riluzole, or has not taken riluzole, for at least 30 days prior to screening\n* If taking concomitant edaravone at study... | {
"compound": "Enoxacin",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT05021536 | Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment | PHASE3 | UNKNOWN | INTERVENTIONAL | false | Amylyx Pharmaceuticals Inc. | The Phoenix Trial is a randomized double blind placebo controlled Phase III trial to evaluate the safety and efficacy of AMX0035 for treatment of ALS | [
{
"type": "OTHER",
"name": "Placebo"
},
{
"type": "DRUG",
"name": "AMX0035"
}
] | 2021-10-28 | https://clinicaltrials.gov/study/NCT05021536 | [
"TARDBP",
"neuroinflammation"
] | [
{
"facility": "Barrow Neurological Institute",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "University of Southern California",
"city": "Los Angeles",
"state": "California",
"coun... | {
"criteria": "Inclusion Criteria:\n\n* Male or female, at least 18 years of age\n* Diagnosis of ALS (definite or clinically probable)\n* Time since onset of first symptom of ALS should be \\<24 months prior to randomization;\n* If the participant is to be treated with riluzole and/or edaravone during the course of t... | {
"compound": "AMX0035",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT04057898 | Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS | PHASE2, PHASE3 | ACTIVE_NOT_RECRUITING | INTERVENTIONAL | false | MediciNova | A Phase 2b/3 multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety and tolerability of MN-166 given to ALS participants for 12 months followed by a 6-month open-label extension phase. | [
{
"type": "DRUG",
"name": "MN-166"
},
{
"type": "DRUG",
"name": "placebo"
}
] | 2020-05-28 | https://clinicaltrials.gov/study/NCT04057898 | [
"neuroinflammation"
] | [
{
"facility": "University of California",
"city": "Orange",
"state": "California",
"country": "United States",
"status": "",
"lat": 33.78779,
"lon": -117.85311
},
{
"facility": "Mayo Clinic",
"city": "Jacksonville",
"state": "Florida",
"country": "United States",
... | {
"criteria": "Major Inclusion Criteria:\n\n* Male or female subjects age 18 - 80 years, inclusive;\n* Diagnosis of familial or sporadic ALS as defined by the El Escorial-Revised (2000) research diagnostic criteria for ALS \\[clinically definite, clinically probable, probable-laboratory-supported\\];\n* ALS onset of ... | {
"compound": "MN-166 (Ibudilast)",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT00855400 | Clinical Trial on the Use of Autologous Bone Marrow Stem Cells in Amyotrophic Lateral Sclerosis | PHASE1, PHASE2 | COMPLETED | INTERVENTIONAL | false | Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia | The purpose of this clinical trial is to asses the feasibility and the security of the intraspinal infusion of autologous bone marrow stem cells for the treatment of Amyotrophic Lateral Sclerosis patients. | [
{
"type": "PROCEDURE",
"name": "Laminectomy and bone marrow stem cells transplantation"
},
{
"type": "PROCEDURE",
"name": "Autologous bone marrow cells collection"
}
] | 2007-02 | https://clinicaltrials.gov/study/NCT00855400 | [
"neuroprotection_motor_neuron_survival"
] | [
{
"facility": "Hospital Universitario Virgen de la Arrixaca",
"city": "El Palmar",
"state": "Murcia",
"country": "Spain",
"status": "",
"lat": 37.93939,
"lon": -1.16095
}
] | {
"criteria": "Inclusion Criteria:\n\n* Diagnose established following the World Federation of Neurology criteria\n* More than 6 and less than 36 months of evolution of the disease\n* Medullar onset of the disease\n* More than 20 and less than 65 years old\n* Forced Vital Capacity equal or superior to 50%\n* Total ti... | {
"compound": "Autologous bone marrow stem cells",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT03204500 | Dual Treatment With Lithium and Valproate in ALS. | PHASE2 | COMPLETED | INTERVENTIONAL | false | El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez | This is a pilot study in 40 subjects with definite ALS to evaluate the efficacy of valproate and lithium carbonate. After a random assignation of the dual treatment vs. placebo, a follow-up of 20 months will allow to know the clinical and functional evolution so as the status of biomarkers under each treatment. | [
{
"type": "COMBINATION_PRODUCT",
"name": "Active treatment with dual therapy"
},
{
"type": "DRUG",
"name": "Placebos"
}
] | 2016-05 | https://clinicaltrials.gov/study/NCT03204500 | [
"histone_deacetylase_inhibition_neuroprotection",
"wnt_signaling_pathway"
] | [
{
"facility": "Instituto Nacional de Neurologia Y Neurocirugia Mvs",
"city": "Mexico City",
"state": "Mexico City",
"country": "Mexico",
"status": "",
"lat": 19.42847,
"lon": -99.12766
}
] | {
"criteria": "Inclusion Criteria:\n\n* patients aged 40 to 70 years\n* of both genders\n* female patients who are either postmenopausal for at least 24 months or who are able to practice 2 methods of contraception.\n* Clinical diagnosis of definite ALS supported by neurophysiological studies, according to El Escoria... | {
"compound": "Valproate and lithium carbonate",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT03136809 | ALS Treatment Extension Study | PHASE1, PHASE2 | UNKNOWN | INTERVENTIONAL | false | Collaborative Medicinal Development Pty Limited | Treatment extension study for ALS/MND patients who participated in phase 1 study CMD-2016-001, completed assessments following six 28-day cycles of treatment, and whom the Investigator considers would benefit from continued CuATSM treatment. | [
{
"type": "DRUG",
"name": "Cu(II)ATSM"
}
] | 2018-01-18 | https://clinicaltrials.gov/study/NCT03136809 | [
"copper_ii_complex"
] | [
{
"facility": "Macquarie University",
"city": "Sydney",
"state": "New South Wales",
"country": "Australia",
"status": "",
"lat": -33.86785,
"lon": 151.20732
}
] | {
"criteria": "Inclusion Criteria:\n\n* Signed informed consent prior to initiation of any study-specific procedures and treatment\n* Documented completion of protocol-specific assessments following completion of six 28-day treatment cycles in study CMD-2016-001\n* Principal Investigator considers the patient would b... | {
"compound": "Cu(II)ATSM",
"targeting_mechanism": "Delivers copper to the central nervous system to restore copper homeostasis and prevent motor neuron degeneration.",
"targeting_mechanism_pmid": "26826269",
"animal_results": "CuATSM treatment extended lifespan in SOD1(G93A) mice and rescued early mortality in... | ||
NCT04226144 | Breath Stacking Technique Associated With Expiratory Muscle Training in Amyotrophic Lateral Sclerosis Patients | NA | TERMINATED | INTERVENTIONAL | false | Escola Superior de Ciencias da Saude | it will be conducted a randomized parallel controlled trial with patients diagnosed with Amyotrophic Lateral Sclerosis (ALS) to compare two techniques to lung recruitment and cough augmentation, to assess their effects on pulmonary function, global functionally, swallowing and ability to speech in these population. | [
{
"type": "DEVICE",
"name": "Breath Stacking Group"
},
{
"type": "DEVICE",
"name": "Breath stacking and EMT"
}
] | 2020-01-06 | https://clinicaltrials.gov/study/NCT04226144 | [
"respiratory_function"
] | [
{
"facility": "Hospital de Apoio de Brasilia",
"city": "Brasília",
"state": "Federal District",
"country": "Brazil",
"status": "",
"lat": -15.77972,
"lon": -47.92972
}
] | {
"criteria": "Inclusion Criteria:\n\n* diagnosis of neuromuscular disease confirmed by neurologists at the referral center for neuromuscular diseases at Brasília prior to screening for recruitment\n* age over 18 years\n* preserved cognition, evidenced by a score greater than or equal to 24 points in the Mini-Mental ... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT00424463 | Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS) | PHASE3 | COMPLETED | INTERVENTIONAL | false | Shionogi | This is a long-term, double-blind, placebo-controlled study of MCI-186 to treat ALS. This study is the long-term extension of Study NCT00330681; Study NCT00330681 is a Phase 3, randomized, double-blind, placebo control, parallel assignment, 24-week study in the treatment of ALS. The objectives of this study are to asse... | [
{
"type": "DRUG",
"name": "MCI-186"
},
{
"type": "DRUG",
"name": "Placebo of MCI-186"
}
] | 2007-01-31 | https://clinicaltrials.gov/study/NCT00424463 | [
"oxidative_stress"
] | [
{
"facility": "National Hospital Organization Miyagi National Hospital",
"city": "Watari-gun",
"state": "Miyagi",
"country": "Japan",
"status": "",
"lat": null,
"lon": null
}
] | {
"criteria": "Inclusion Criteria:\n\n* Patients who ware completed drug administration without discontinuation in the preceding confirmatory study NCT00330681.\n\nExclusion Criteria:\n\n* Patients with such complications as Parkinson's disease, schizophrenia, dementia, renal failure, or other severe complication, an... | {
"compound": "MCI-186",
"targeting_mechanism": "Reduces oxidative stress through antioxidant mechanisms.",
"targeting_mechanism_pmid": "38473944",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT05176093 | A 6-Month Extension Study to Assess the Long-Term Safety of Engensis in Amyotrophic Lateral Sclerosis | PHASE2 | COMPLETED | INTERVENTIONAL | false | Helixmith Co., Ltd. | The purpose of this study is to evaluate the long-term safety of intramuscular administration of Engensis in Participants with Amyotrophic Lateral Sclerosis who were previously randomized, received treatment, and completed the Day 180 Visit of Study VMALS-002-2. Safety will be assessed by incidences of treatment-emerge... | [
{
"type": "BIOLOGICAL",
"name": "Engensis"
},
{
"type": "OTHER",
"name": "Placebo"
}
] | 2021-11-14 | https://clinicaltrials.gov/study/NCT05176093 | [
"motor_neuron_degeneration"
] | [
{
"facility": "Austin Neuromuscular Center",
"city": "Austin",
"state": "Texas",
"country": "United States",
"status": "",
"lat": 30.26715,
"lon": -97.74306
},
{
"facility": "Hanyang University Medical Center",
"city": "Seoul",
"state": "",
"country": "South Korea",
... | {
"criteria": "Inclusion Criteria:\n\n* Participants who complete the Day 180 Visit in VMALS-002-2 are eligible to enroll in this extension study, VMALS-002-2b.\n\nExclusion Criteria:\n\n\\- None",
"sex": "ALL",
"min_age": "18 Years",
"max_age": "80 Years",
"healthy_volunteers": false,
"std_ages": [
"AD... | {
"compound": "Engensis",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT06719947 | HD-tDCS in Amyotrophic Lateral Sclerosis: A Multicenter Randomized Controlled Trial | PHASE2, PHASE3 | RECRUITING | INTERVENTIONAL | false | Universidade Federal do Rio Grande do Norte | Amyotrophic Lateral Sclerosis (ALS) is a nervous system disease that causes muscle weakness and rapidly progresses to the loss of mobility and functionality. Studies suggest that High-Definition Transcranial Direct Current Stimulation (HD-tDCS) is a technique for modulating motor cortical hyperexcitability. However, ev... | [
{
"type": "DEVICE",
"name": "Active HD-tDCS"
},
{
"type": "DEVICE",
"name": "Simulated HD-tDCS"
}
] | 2025-11-28 | https://clinicaltrials.gov/study/NCT06719947 | [
"cortical_hyperexcitability"
] | [
{
"facility": "Universidade de Brasília - Campus Ceilândia",
"city": "Brasília",
"state": "Federal District",
"country": "Brazil",
"status": "RECRUITING",
"lat": -15.77972,
"lon": -47.92972
},
{
"facility": "PneumoCardioVascular Lab - HUOL/UFRN",
"city": "Natal",
"state":... | +55(84)99426-7896 | guilherme.fregonezi@ufrn.br | {
"criteria": "Inclusion Criteria:\n\n* Both sexes; diagnosis of ALS according to the revised El Escorial criteria;\n* Age between 18 and 80 years;\n* Forced Vital Capacity greater than 50% of predicted;\n* Sniff nasal inspiratory pressure greater than 40 cmH2O;\n* A telephone number to contact the care team and who ... | {
"compound": "unknown",
"targeting_mechanism": "High-Definition Transcranial Direct Current Stimulation modulates motor cortical hyperexcitability, potentially targeting the diaphragmatic motor cortex.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_fro... |
NCT05568615 | Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects With ALS | PHASE3 | COMPLETED | INTERVENTIONAL | false | Shionogi | The purpose of this study is to evaluate the safety of oral edaravone at a dose of 105 mg administered once daily for 10 days out of a 14-day period, followed by a 14-day drug-free period. This study will be continued until the earlier date when oral edaravone is commercially available at each site in Japan or August 2... | [
{
"type": "DRUG",
"name": "MT-1186"
}
] | 2022-10-26 | https://clinicaltrials.gov/study/NCT05568615 | [
"oxidative_stress"
] | [
{
"facility": "National Hospital Organization Higashinagoya National Hospital",
"city": "Nagoya",
"state": "Aichi-ken",
"country": "Japan",
"status": "",
"lat": 35.18147,
"lon": 136.90641
},
{
"facility": "National Hospital Organization Chibahigashi National Hospital",
"city"... | {
"criteria": "Inclusion Criteria:\n\n* Subjects must provide a signed and dated informed consent form (ICF) to participate in the study.\n* Subjects must be able (in the judgment of the Investigator) to understand the nature of the study and all risks involved with participation in the study\n* Subjects must be will... | {
"compound": "MT-1186",
"targeting_mechanism": "Free radical scavenger and antioxidant that reduces oxidative stress",
"targeting_mechanism_pmid": "38473944",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT02288091 | A Pilot Study of Inosine in Amyotrophic Lateral Sclerosis (ALS) | PHASE1 | COMPLETED | INTERVENTIONAL | false | Massachusetts General Hospital | This is a single center, open label, 12-week study of inosine treatment. Inosine treatment leads to an increase in the levels of urate (uric acid) in the blood.
The primary objective of the study is to determine the tolerability of oral administration of inosine.
Secondary study objectives include the measurement of ... | [
{
"type": "DRUG",
"name": "Inosine"
}
] | 2015-01 | https://clinicaltrials.gov/study/NCT02288091 | [
"oxidative_stress"
] | [
{
"facility": "Massachusetts General Hospital",
"city": "Boston",
"state": "Massachusetts",
"country": "United States",
"status": "",
"lat": 42.35843,
"lon": -71.05977
}
] | {
"criteria": "Inclusion Criteria:\n\n1. Age 18 years or older.\n2. Sporadic or familial ALS diagnosed as possible, laboratory-supported probable, probable, or definite as defined by revised El Escorial criteria (Appendix 1).\n3. Capable of providing informed consent and following trial procedures.\n4. Serum urate \\... | {
"compound": "Inosine",
"targeting_mechanism": "Increases urate levels to provide antioxidant protection against oxidative stress",
"targeting_mechanism_pmid": "38473944",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT06315608 | MRG-001 in Patients With Amyotrophic Lateral Sclerosis | PHASE2 | UNKNOWN | INTERVENTIONAL | false | MedRegen LLC | The proposed study is an Open-Label, Single-Dose Study to Assess the Safety, and Pharmacodynamics (PD) signals of MRG-001 in Patients with Amyotrophic Lateral Sclerosis (ALS). MRG-001 will be administered subcutaneously 3 times per week for 2 weeks. This cycle will be repeated for 3 months. In total, patients are expec... | [
{
"type": "DRUG",
"name": "MRG-001"
}
] | 2025-07-01 | https://clinicaltrials.gov/study/NCT06315608 | [
"neuroinflammation"
] | [] | 443-759-8563 | info@medregenco.com | {
"criteria": "Inclusion Criteria:\n\n* Able to provide written informed consent (either from patient or patient's legally acceptable representative and complying with study procedures, in the PI's opinion.\n* Male or female patients between 18-75 years.\n* Sporadic or familial ALS diagnosed as clinically possible, p... | {
"compound": "MRG-001",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT04322149 | Multiple Doses of AT-1501-A201 in Adults With ALS | PHASE2 | COMPLETED | INTERVENTIONAL | false | Anelixis Therapeutics, LLC | This is a Phase 2a, multi-center, open label, multiple dose study of AT-1501, a humanized monoclonal antibody antagonist to CD40 ligand (CD40L). Approximately 54 adults with Amyotrophic Lateral Sclerosis (ALS) will be enrolled into the study in the United States and Canada at approximately 13 ALS treatment sites.
Part... | [
{
"type": "DRUG",
"name": "AT-1501"
}
] | 2020-10-16 | https://clinicaltrials.gov/study/NCT04322149 | [
"CD40L"
] | [
{
"facility": "Barrows Neurological Institute",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "University of California Irvine",
"city": "Orange",
"state": "California",
"country": ... | {
"criteria": "Inclusion Criteria:\n\n1. ALS diagnosed as possible, laboratory supported probable, probable, or definite as defined by revised El Escorial criteria\n2. ALS Functional Rating Scale - Revised (ALSFRS-R) Aggregate score of 37 or greater\n3. No more than 24 months from diagnosis\n\nExclusion Criteria:\n\n... | {
"compound": "AT-1501",
"targeting_mechanism": "Humanized monoclonal antibody antagonist to CD40 ligand (CD40L) that modulates immune response",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT07091799 | Interest of Measuring P2X4 Receptors on Blood Monocytes as a Diagnostic Marker in Amyotrophic Lateral Sclerosis: P2X4 as a Diagnostic Biomarker for ALS | NA | RECRUITING | INTERVENTIONAL | false | University Hospital, Bordeaux | Amyotrophic lateral sclerosis (ALS) is the most common form of motor neuron disease and is characterized by the degeneration of motor neurons leading to progressive paralysis and death within 3 to 5 years after diagnosis. To date, no key mechanism had been identified. Our associated laboratory has identified the P2X4 p... | [
{
"type": "DIAGNOSTIC_TEST",
"name": "P2X4 receptors in blood samples"
}
] | 2026-01-15 | https://clinicaltrials.gov/study/NCT07091799 | [
"P2X4"
] | [
{
"facility": "Hôpital Pellegrin",
"city": "Bordeaux",
"state": "",
"country": "France",
"status": "RECRUITING",
"lat": 44.84124,
"lon": -0.58046
}
] | 05 57 82 13 70 | gwendal.le-masson@chu-bordeaux.fr | {
"criteria": "Inclusion Criteria:\n\n* For ALS group: Person presenting a probable or confirmed diagnosis of ALS according to the criteria of EI Escorial.\n* Adult.\n* Person affiliated or beneficiary of a social security scheme.\n* Free, informed and written consent signed by the participant or by a third person (i... | {
"compound": "P2X4 receptors in blood samples",
"targeting_mechanism": "P2X4 purinergic pathway involved in ALS pathogenesis via intracellular calcium dysregulation",
"targeting_mechanism_pmid": "27453058",
"animal_results": "Several ALS-related misfolded proteins including mutants of SOD1 or TDP-43 lead to a ... |
NCT06021938 | Alleviating Persistent Dyspnea in Amyotrophic Lateral Sclerosis Patients Treated With Non-Invasive Ventilation Through Immersive Virtual Reality | NA | RECRUITING | INTERVENTIONAL | false | Assistance Publique - Hôpitaux de Paris | The evolution of amyotrophic lateral sclerosis (ALS) is marked by dyspnea, anxiety and pain, major determinants of suffering induced by this disease. The only palliative treatment for respiratory failure is non-invasive ventilation (NIV), which compensates failing respiratory muscles and relieves dyspnea, improves qual... | [
{
"type": "DEVICE",
"name": "Immersive virtual reality (IVR) & Music therapy"
}
] | 2024-04-04 | https://clinicaltrials.gov/study/NCT06021938 | [] | [
{
"facility": "Service de Pneumologie",
"city": "Paris",
"state": "France",
"country": "France",
"status": "RECRUITING",
"lat": 48.85341,
"lon": 2.3488
}
] | 01 42 16 77 71 | capucine.morelot@aphp.fr | {
"criteria": "Inclusion Criteria:\n\n* ≥ 18 years old\n* Diagnosis of ALS confirmed according to the revised criteria of El Escorial\n* Respiratory failure due to diaphragmatic dysfunction treated by non-invasive ventilation for more than a month\n* Care provided in an ambulatory setting (day care hospital)\n* Persi... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
NCT06649955 | Controlling Amyotrophic Lateral Sclerosis Motor Neuron Excitability Study | NA | RECRUITING | INTERVENTIONAL | false | PathMaker Neurosystems Inc. | Following completion of the ALS Early Feasibility Study of the MyoRegulator® device for treatment of ALS (NCT06165172), the CALM study will further assess the feasibility of the MyoRegulator® device to treat ALS in an expanded number of individuals with ALS. CALM will gather additional preliminary evidence of clinical ... | [
{
"type": "DEVICE",
"name": "Multi-site direct current stimulation (DCS)"
}
] | 2025-02-10 | https://clinicaltrials.gov/study/NCT06649955 | [] | [
{
"facility": "Beth Israel Deaconess Medical Center",
"city": "Boston",
"state": "Massachusetts",
"country": "United States",
"status": "RECRUITING",
"lat": 42.35843,
"lon": -71.05977
}
] | 617-667-3083 | tokanlom@bidmc.harvard.edu | {
"criteria": "Inclusion Criteria:\n\n1. 18-80 years of age inclusive\n2. Sporadic or familial ALS diagnosed as clinically possible, probable, lab-supported probable, or definite ALS as defined by revised El Escorial criteria\n3. Less than or equal to 3 years since ALS symptom onset\n4. Slow Vital Capacity ≥ 50% of p... | {
"compound": "unknown",
"targeting_mechanism": "Direct current stimulation to modulate motor neuron excitability.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
NCT04490148 | Remote Pulmonary Function Testing and Nurse Coaching in ALS | NA | COMPLETED | INTERVENTIONAL | false | Milton S. Hershey Medical Center | Comparison of respiratory outcomes in patients receiving telemedicine-guided remote pulmonary function testing (rPFT) with or without the additional support of nurse coaching. This is a randomized controlled study which assesses the effects rPFT and coaching on respiratory outcomes and quality of life. | [
{
"type": "DEVICE",
"name": "remote pulmonary function testing"
},
{
"type": "DEVICE",
"name": "standard pulmonary function testing"
},
{
"type": "BEHAVIORAL",
"name": "Nurse Respiratory Health Coaching (NRHC)"
}
] | 2020-07-01 | https://clinicaltrials.gov/study/NCT04490148 | [] | [
{
"facility": "Hershey Medical Center ALS Clinic",
"city": "Hershey",
"state": "Pennsylvania",
"country": "United States",
"status": "",
"lat": 40.28592,
"lon": -76.65025
}
] | {
"criteria": "Inclusion Criteria:\n\nPatients:\n\n1. Possess a diagnosis of definite, probable, probable laboratory-supported, or possible ALS by revised El Escorial research criteria \\[Brooks2000\\].\n2. Be 18 years of age or older.\n3. Have a caregiver available to participate in the study\n4. Symptom onset withi... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT06819358 | Individualized Functional Imaging-Guided Repetitive Transcranial Magnetic Stimulation (rTMS) for Treating Postural Gait Disorders in Patients with Amyotrophic Lateral Sclerosis (ALS): a Randomized, Crossover, Controlled, Double-Blind Clinical Study | EARLY_PHASE1 | NOT_YET_RECRUITING | INTERVENTIONAL | false | Peking University Third Hospital | This study is a randomized, crossover, controlled, double-blind clinical trial. Patients (n=45) were randomly divided into Group A and Group B. Patients in Group A will receive 2 weeks (10800 Hz daily, 5 days×2) of Transcranial magnetic stimulation（TMS） treatment, while patients in Group B will receive sham stimulation... | [
{
"type": "DEVICE",
"name": "Transcranial Magnetic Stimulation"
}
] | 2025-02-14 | https://clinicaltrials.gov/study/NCT06819358 | [] | [] | +86 15801224009 | 15801224009@163.COM | {
"criteria": "Inclusion Criteria:\n\n1. Aged 18-80 years;\n2. Diagnosis of motor neuron disease at probable level or above based on Estorial criteria;12\n3. Meet UMND ALS diagnosis criteria: at least three segments of upper motor neuron damage localized to 1-2 muscles, or EMG indicating loss of innervation in 1-2 mu... | {
"compound": "unknown",
"targeting_mechanism": "Repetitive transcranial magnetic stimulation to modulate motor cortex function and motor neuron activity.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ... |
NCT01232738 | Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | COMPLETED | INTERVENTIONAL | false | Yunxia Wang, MD | ALS is a disorder that weakens motor strength and lung function. Rapid loss of motor neurons in the brain and spinal cord of ALS patients causes the symptoms of increasing weakness and loss of muscle function. While there are drugs to help relieve symptoms of ALS, there is no cure for ALS.
Rasagiline is a drug with po... | [
{
"type": "DRUG",
"name": "rasagiline"
}
] | 2011-12 | https://clinicaltrials.gov/study/NCT01232738 | [
"Monoamine oxidase B"
] | [
{
"facility": "Phoenix Neurological Institute",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "California Pacific Medical Center",
"city": "San Francisco",
"state": "California",
"c... | {
"criteria": "Inclusion Criteria:\n\n1. A clinical diagnosis of laboratory-supported probable, probable, or definite ALS, according to a modified El Escorial criteria, by the study investigator (Appendix IV).\n2. 21 to 80 years of age inclusive.\n3. VC greater or equal to 75% of predicted at screening and baseline.\... | {
"compound": "rasagiline",
"targeting_mechanism": "Monoamine oxidase B (MAO-B) inhibition with neuroprotective properties.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT05470478 | iBCI Optimization for Veterans With Paralysis | NA | NOT_YET_RECRUITING | INTERVENTIONAL | false | VA Office of Research and Development | VA research has been advancing a high-performance brain-computer interface (BCI) to improve independence for Veterans and others living with tetraplegia or the inability to speak resulting from amyotrophic lateral sclerosis, spinal cord injury or stoke. In this project, the investigators enhance deep learning neural ne... | [
{
"type": "DEVICE",
"name": "Mobile neural decoding platform (mobile iBCI)"
}
] | 2026-10-02 | https://clinicaltrials.gov/study/NCT05470478 | [] | [
{
"facility": "Providence VA Medical Center, Providence, RI",
"city": "Providence",
"state": "Rhode Island",
"country": "United States",
"status": "",
"lat": 41.82399,
"lon": -71.41283
}
] | (401) 273-7100 | Kate.Barnabe@va.gov | {
"criteria": "Inclusion Criteria:\n\n* Inclusion criteria are extensive and are determined by the associated BrainGate IDE(clinicaltrials.gov # NCT00912041)\n* Informally, participants will be tetraplegic or anarthric with little or no functional use of the arms and legs\n\nExclusion Criteria:\n\n* Exclusion criteri... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
NCT00542412 | CARE Canadian ALS Riluzole Evaluation | PHASE4 | COMPLETED | INTERVENTIONAL | false | Sanofi | Evaluate the efficacy of riluzole 50-mg bid defined by comparing the percentage of riluzole-treated subjects who experienced death, permanently assisted ventilation (PAV) or tracheostomy, to a group of recent historical controls for the treatment of amyotrophic lateral sclerosis (ALS). | [
{
"type": "DRUG",
"name": "Riluzole"
}
] | 2001-01 | https://clinicaltrials.gov/study/NCT00542412 | [
"glutamate"
] | [
{
"facility": "Sanofi-Aventis",
"city": "Laval",
"state": "Quebec",
"country": "Canada",
"status": "",
"lat": 45.56995,
"lon": -73.692
}
] | {
"criteria": "Inclusion Criteria:\n\n* Diagnosis of ALS confirmed by the following definition:\n\n (a)\"Probable\" or \"Definite\" Amyotrophic Lateral Sclerosis (ALS) according to the El Escorial criteria(b)\"Peripheral\" onset form (limb involvement) or a \"Bulbar\" form of ALS with a duration of five years, based... | {
"compound": "Riluzole",
"targeting_mechanism": "Riluzole is an anti-glutamatergic agent that blocks glutamatergic neurotransmission in the CNS to exert neuroprotective effects by targeting excitotoxicity.",
"targeting_mechanism_pmid": "31141951",
"animal_results": "Riluzole does not improve lifespan or motor ... | ||
NCT03537807 | Expanded Access Protocol of BHV-0223 for Patients With Amyotrophic Lateral Sclerosis (ALS) | Expanded Access | NO_LONGER_AVAILABLE | EXPANDED_ACCESS | true | Biohaven Pharmaceuticals, Inc. | This is an open label expanded access protocol for the treatment of up to approximately 250 adult patients with amyotrophic lateral sclerosis (ALS) who have difficulty swallowing oral riluzole tablets and may be able to derive benefit from treatment with an alternative oral formulation of riluzole. | [
{
"type": "DRUG",
"name": "Riluzole"
}
] | https://clinicaltrials.gov/study/NCT03537807 | [
"glutamate"
] | [] | {
"criteria": "Inclusion Criteria:\n\n* Patients with diagnosed ALS of any type or duration\n* Current or previous treatment with oral riluzole tablets, or patients who have never taken riluzole oral tablets, or patients who have successfully completed a clinical trial with BHV-0223 and were not withdrawn prematurely... | {
"compound": "Riluzole",
"targeting_mechanism": "Riluzole is a benzothiazole derivative that blocks glutamatergic neurotransmission in the CNS to exert neuroprotective effects.",
"targeting_mechanism_pmid": "32847483",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurpos... | |||
NCT04140136 | The Efficacy and Safety of Vitamin E Mixed Tocotrienols In Patients With Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | UNKNOWN | INTERVENTIONAL | false | University of Malaya | There is currently no effective treatment in ALS. Oxidative stress, probably interacting with other neurodegenerative processes, is hypothesized to play a leading role in pathogenesis. These include mechanisms that promote glutamate excitotoxicity, mitochondrial dysfunction and axonal dysfunction.
In a transgenic mous... | [
{
"type": "DIETARY_SUPPLEMENT",
"name": "Tocotrienols"
},
{
"type": "DIETARY_SUPPLEMENT",
"name": "Placebo"
}
] | 2019-06-17 | https://clinicaltrials.gov/study/NCT04140136 | [
"oxidative_stress",
"glutamate_excitotoxicity",
"mitochondrial_dysfunction"
] | [
{
"facility": "Clinical Investigation Centre (CIC)",
"city": "Kuala Lumpur",
"state": "",
"country": "Malaysia",
"status": "RECRUITING",
"lat": 3.1412,
"lon": 101.68653
}
] | +603-79492622 | wangpl@ummc.edu.my | {
"criteria": "Inclusion Criteria:\n\n* Patients who have a decrease of 1 to 4 points on the ALSFRS-R score during the 12-weeks observation period prior to screening and enrollment\n* Patients of less than 2 years after the diagnosis of ALS.\n* Patients without respiratory symptoms (orthopnea, dyspnea)\n* Capable of ... | {
"compound": "Tocotrienols",
"targeting_mechanism": "Tocotrienols are a form of vitamin E that act as antioxidants to reduce oxidative stress and its contribution to neurodegenerative pathogenesis.",
"targeting_mechanism_pmid": "33274002",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed... |
NCT00879593 | Nocturnal PtcCO2 Monitoring in Patients With Amyotrophic Lateral Sclerosis (ALS) | NA | COMPLETED | INTERVENTIONAL | false | Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche | Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease affecting motoneurons, with a prevalence around 5/100.000. Respiratory muscle involvement is a major feature in ALS and remains the main prognostic factor. Timing and rate of progression of this respiratory muscle involvement is also highly variable amo... | [
{
"type": "DEVICE",
"name": "PtcCO2"
}
] | 2009-04 | https://clinicaltrials.gov/study/NCT00879593 | [] | [
{
"facility": "PEREZ",
"city": "Lille",
"state": "",
"country": "France",
"status": "",
"lat": 50.63391,
"lon": 3.05512
},
{
"facility": "Pôle des maladies respiratoires et service EFR- Centre hospitalier Regional Universitaire",
"city": "Lille",
"state": "",
"country... | {
"criteria": "Inclusion Criteria:\n\n* Amyotrophic lateral sclerosis :definite, probable or probable with EMG (Airlie House Criteria, 1998).\n* Forced vital capacity \\>70% pred.\n* Daytime PaCO2 \\<43 mmHg.\n* Venous HCO3- \\<28 mmol/L\n\nExclusion Criteria:\n\n* Patients unable to perform pulmonary function tests ... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT02655614 | A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis | PHASE1 | COMPLETED | INTERVENTIONAL | false | Genentech, Inc. | This first-in-human, double-blind, placebo-controlled Phase I study will be conducted in participants with amyotrophic lateral sclerosis (ALS) to explore safety, tolerability, and pharmacokinetic (PK) properties of GDC-0134. It will include three components: a Single-Ascending-Dose (SAD) stage, a Multiple-Ascending-Dos... | [
{
"type": "DRUG",
"name": "GDC-0134"
},
{
"type": "DRUG",
"name": "Placebo"
},
{
"type": "DRUG",
"name": "Rabeprazole"
},
{
"type": "DRUG",
"name": "Midazolam"
},
{
"type": "DRUG",
"name": "Caffeine"
}
] | 2016-05-31 | https://clinicaltrials.gov/study/NCT02655614 | [
"TARDBP"
] | [
{
"facility": "Forbes Norris Mda/als Ctr; Research Center",
"city": "San Francisco",
"state": "California",
"country": "United States",
"status": "",
"lat": 37.77493,
"lon": -122.41942
},
{
"facility": "Mayo Clinic Hospital - Florida",
"city": "Jacksonville",
"state": "Fl... | {
"criteria": "Inclusion Criteria:\n\n* Male or female participants with a diagnosis of possible, laboratory-supported probable, probable, or definite ALS according to modified El Escorial criteria\n* Upright forced vital capacity of at least 50 percent (%)\n* Ability to fast from food for 8 hours prior to dosing and... | {
"compound": "GDC-0134",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT03474263 | IC14 for Rapidly Progressive Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | WITHDRAWN | INTERVENTIONAL | false | Implicit Bioscience | Patients with rapidly progressive ALS will be assigned to IC14 intravenously on Day 1-4. This 4-day course will be repeated on Days 8-11. Patients will all undergo MR-PET scans at two time points: before treatment onset and after the last treatment cycle. This scan will measure areas of ALS disease activity and assess ... | [
{
"type": "BIOLOGICAL",
"name": "Biologic: IC14 (monoclonal antibody against human CD14)"
}
] | 2019-09-01 | https://clinicaltrials.gov/study/NCT03474263 | [
"CD14",
"neuroinflammation"
] | [
{
"facility": "Royal Brisbane & Women's Hospital",
"city": "Herston",
"state": "Queensland",
"country": "Australia",
"status": "",
"lat": -27.44453,
"lon": 153.01852
}
] | {
"criteria": "Inclusion Criteria:\n\n1. Capable of providing informed consent and informed consent form signed prior to initiation of any study-specific procedures.\n2. Familial or sporadic ALS defined as clinically possible, probable, or definite by El Escorial Criteria.\n3. Rapidly progressive ALS defined by the R... | {
"compound": "IC14",
"targeting_mechanism": "Monoclonal antibody against human CD14 to modulate innate immune activation and neuroinflammation in ALS.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT02714036 | A Biomarker Study to Evaluate MN-166 in Subjects With Amyotrophic Literal Sclerosis (ALS) | PHASE1, PHASE2 | COMPLETED | INTERVENTIONAL | false | MediciNova | This is a multi-center, open-label study of MN-166 (ibudilast) in subjects with ALS. To be eligible subjects must meet the El Escorial criteria of possible, laboratory-supported probable, probable, or definite criteria for a diagnosis of ALS. Safety, tolerability, blood, neuro-imaging biomarkers, and clinical outcomes ... | [
{
"type": "DRUG",
"name": "ibudilast"
},
{
"type": "DRUG",
"name": "Ibudilast"
}
] | 2016-05-06 | https://clinicaltrials.gov/study/NCT02714036 | [
"neuroinflammation"
] | [
{
"facility": "Massachusetts General Hospital",
"city": "Boston",
"state": "Massachusetts",
"country": "United States",
"status": "",
"lat": 42.35843,
"lon": -71.05977
},
{
"facility": "South Shore Neurologic Associates, P.C.",
"city": "Patchogue",
"state": "New York",
... | {
"criteria": "Inclusion Criteria:\n\n1. Subjects must be diagnosed as having possible, probable, probable-laboratory supported, or definite ALS, either sporadic or familial according to modified El Escorial criteria.\n2. Age 18 or above, able to provide informed consent, and safely comply with study procedures.\n3. ... | {
"compound": "ibudilast",
"targeting_mechanism": "Inhibitor of neuroinflammation and glial cell activation to reduce CNS inflammation in ALS.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT06704347 | Safety Study of XT-150 in Participants With ALS | PHASE1 | NOT_YET_RECRUITING | INTERVENTIONAL | false | Xalud Therapeutics, Inc. | This is a Phase 1, open-label, multi-center safety study of XT-150 in adult participants with Amyotrophic Lateral Sclerosis (ALS).
Participants providing informed consent and meeting all study eligibility criteria will be enrolled in the study and will receive a single injection of XT-150 at the Baseline visit. Follow... | [
{
"type": "BIOLOGICAL",
"name": "XT-150"
}
] | 2027-03 | https://clinicaltrials.gov/study/NCT06704347 | [
"neuroinflammation"
] | [
{
"facility": "Barrow Neurological Institute (St. Joseph's)",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "Johns Hopkins University",
"city": "Baltimore",
"state": "Maryland",
"co... | 212-301-6673 | medical.information@xaludthera.com | {
"criteria": "Key Inclusion Criteria:\n\n* Adults between 18 and 80 years of age\n* Male or female, if of childbearing potential or sexually active, strict contraception required\n* Have ALS diagnosed by a doctor (specifically, sporadic or familial ALS diagnosed as clinically probable, lab-supported probable or defi... | {
"compound": "XT-150",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT02623699 | An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS) | PHASE3 | COMPLETED | INTERVENTIONAL | false | Biogen | The primary objectives of Parts A and B of this study are to evaluate the safety, tolerability, and pharmacokinetics (PK) of ascending doses of tofersen in adults with ALS and a documented superoxide dismutase 1 (SOD1) mutation. The primary objective of Part C of this study is to evaluate the clinical efficacy of tofer... | [
{
"type": "DRUG",
"name": "Tofersen"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2016-01-20 | https://clinicaltrials.gov/study/NCT02623699 | [
"SOD1"
] | [
{
"facility": "Barrow Neurological Institute",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "University of California San Diego Medical Center",
"city": "La Jolla",
"state": "Californi... | {
"criteria": "Key Inclusion Criteria: Part A and B\n\n* Weakness attributable to ALS and documented SOD1 mutation at Screening Visit 2.\n* A forced vital capacity (FVC) ≥50% of predicted value as adjusted for sex, age, and height (from the sitting position). Participants with stable FVC \\<50% but ≥45%, whose FVC ha... | {
"compound": "Tofersen",
"targeting_mechanism": "Antisense oligonucleotide that targets and reduces SOD1 mRNA expression in patients with SOD1 mutations.",
"targeting_mechanism_pmid": "37975798",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from... | ||
NCT05328492 | Volume Mode Non-invasive Ventilation in Amyotrophic Lateral Sclerosis | NA | UNKNOWN | INTERVENTIONAL | false | University Hospitals Coventry and Warwickshire NHS Trust | The purpose of this study is to assess the efficacy of using intelligent volume assured pressure support (iVAPS-AE) versus spontaneous timed (ST) modes of non-invasive ventilation (NIV) in patients diagnosed with amyotrophic lateral sclerosis (ALS).
The investigators believe that the use of iVAPS-AE mode NIV over a 90... | [
{
"type": "DEVICE",
"name": "iVAPS-AE"
},
{
"type": "DEVICE",
"name": "ST-mode"
}
] | 2022-03-15 | https://clinicaltrials.gov/study/NCT05328492 | [] | [
{
"facility": "University Hospital Coventry and Warwickshire NHS Trust",
"city": "Coventry",
"state": "West Midlands",
"country": "United Kingdom",
"status": "RECRUITING",
"lat": 52.40656,
"lon": -1.51217
}
] | 02476966734 | edward.parkes@uhcw.nhs.uk | {
"criteria": "Inclusion Criteria:\n\nPatients with respiratory failure secondary to ALS (diagnosed either at an MND MDT or specialist neurology clinic) according to criteria set out in the NICE guideline (NG42) (2016); Motor neurone disease: assessment and management.\n\n* Patients able to provide informed consent t... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
NCT07082192 | A Study to Evaluate the Efficacy and Safety of Different Doses of CB03-154 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS) | PHASE2, PHASE3 | NOT_YET_RECRUITING | INTERVENTIONAL | false | Shanghai Zhimeng Biopharma, Inc. | The goal of this clinical trial is to learn if drug CB03-154 works to treat ALS in adults. It will also learn about the safety of drug CB03-154.
The main questions it aims to answer are:
* Does drug CB03-154 have an effect on delaying disease progression, improving function, and prolonging survival in adult ALS patie... | [
{
"type": "DRUG",
"name": "Test drug CB03-154 5mg group"
},
{
"type": "DRUG",
"name": "Test drug CB03-154 10mg group"
},
{
"type": "DRUG",
"name": "Test drug CB03-154 15mg group"
},
{
"type": "DRUG",
"name": "Placebo Group"
}
] | 2025-09-29 | https://clinicaltrials.gov/study/NCT07082192 | [
"Tau"
] | [] | {
"criteria": "Inclusion Criteria:\n\n1. Agree to follow the treatment plan and trial procedures of this study, and sign the written informed consent form.\n2. Male or female, aged 18 to 65 years, inclusive.\n3. The weight of subjects during the screening period must not be less than 45 kg, and the BMI must not be le... | {
"compound": "CB03-154",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT00409721 | The Effect of Memantine on Functional Outcomes and Motor Neuron Degeneration in Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | COMPLETED | INTERVENTIONAL | false | University of Alberta | The purpose of the study is to investigate the effects of memantine in ALS patients using functional outcome measures. | [
{
"type": "DRUG",
"name": "Memantine"
}
] | 2007-03 | https://clinicaltrials.gov/study/NCT00409721 | [
"glutamate_excitotoxicity"
] | [
{
"facility": "Calgary ALS Neuromuscular Clinic",
"city": "Calgary",
"state": "Alberta",
"country": "Canada",
"status": "",
"lat": 51.05011,
"lon": -114.08529
},
{
"facility": "University of Alberta ALS Clinic",
"city": "Edmonton",
"state": "Alberta",
"country": "Cana... | {
"criteria": "Inclusion Criteria:\n\n* El Escorial Classification of laboratory supported probable, probable,or definite ALS\n* Age 18 - 80 years,\n* ALS symptoms for no more than 3 years,\n* FVC greater than or equal to 60% predicted,\n* Riluzole naïve or have been on a stable dose of Riluzole for at least 2 months... | {
"compound": "Memantine",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT07161999 | Study of COYA 302 for the Treatment of ALS | PHASE2, PHASE3 | RECRUITING | INTERVENTIONAL | false | Coya Therapeutics | The ALSTARS trial will be conducted across 20-25 sites in the US and Canada, and will evaluate the safety and efficacy of an investigational treatment called COYA 302 for adults with Amyotrophic Lateral Sclerosis (ALS).
COYA 302 is an investigational and proprietary biologic combination therapy with a dual immunomodul... | [
{
"type": "DRUG",
"name": "COYA 302"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2025-10-01 | https://clinicaltrials.gov/study/NCT07161999 | [
"neuroinflammation"
] | [
{
"facility": "Barrow Neurological Institute",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "RECRUITING",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "Cedars-Sinai Medical Center",
"city": "Los Angeles",
"state": "California",
"... | 800-587-8170 | clinicaltrials@coyatherapeutics.com | {
"criteria": "Key Inclusion Criteria:\n\n1. Sporadic or familial ALS, diagnosed as clinically probable, lab-supported probable, or definite ALS according to the revised El Escorial criteria\n2. Male or female participants aged 18 to 80\n3. Time since onset of ALS symptoms ≤28 months from Screening.\n4. ALSFRS-R tota... | {
"compound": "COYA 302",
"targeting_mechanism": "Dual immunomodulatory mechanism that enhances anti-inflammatory function of regulatory T cells (Tregs) and suppresses inflammation produced by activated monocytes and macrophages.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_p... |
NCT01935518 | A Clinical Trial of Safety and Efficacy of Fasudil in Subjects With Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | UNKNOWN | INTERVENTIONAL | false | Peking University Third Hospital | This study will examine whether fasudil is effective and safe in treating patients with amyotrophic lateral sclerosis (ALS). | [
{
"type": "DRUG",
"name": "Fasudil"
}
] | 2013-09 | https://clinicaltrials.gov/study/NCT01935518 | [
"Rho kinase"
] | [
{
"facility": "Peking University Third Hospital",
"city": "Beijing",
"state": "",
"country": "China",
"status": "RECRUITING",
"lat": 39.9075,
"lon": 116.39723
}
] | 0086-15611908107 | dsfan@sina.com | {
"criteria": "Inclusion Criteria:\n\n* Clinical diagnosis of laboratory-supported probable, probable, or definite ALS\n* Age: 18-70 years\n* Disease duration: 3-36 months\n* Forced vital capacity: at least 60% of predicted\n* ALSFRS-R: at least 30, respiratory items: at least 10\n* Decline of ALSFRS-R in the last 3 ... | {
"compound": "Fasudil",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.